AU731580B2 - Precursors of catalytic antibodies - Google Patents

Description

WO 97/35887 PCT/AU97/00194 -1- Precursors of Catalytic antibodies The present invention is directed generally to catalytic antibodies and, more particularly, to a novel method of producing same. The method of the present invention is predicated in part on the exploitation of the products of catalysis to induce B cell mitogenesis. In a preferred embodiment, a growth factor having an ability to induce B cell mitogenesis is linked to a target antigen to which catalytic antibodies are sought. B cell mitogenesis is then dependent on the catalytic cleavage of the antigen portion of the growth factor by catalytic antibodies on the surface of B cells. The method of the present invention is useful for generating catalytic antibodies for both therapeutic and diagnostic purposes.

Sequence Identity Numbers (SEQ ID NOs.) for the nucleotide and amino acid sequences referred to in the specification are defined following the Examples.

Throughout this specification, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element or integer or group of elements or integers but not the exclusion of any other element or integer or group of elements or integers.

The rapidly increasing sophistication of recombinant DNA technology is greatly facilitating research and development in the medical and allied health fields. A particularly important area of research is the use of recombinant antigens to stimulate immune response mechanisms and outcomes. However, until now, recombinant techniques have not been particularly effective in the generation of catalytic antibodies.

Catalytic antibodies are highly substrate specific catalysts which can be used, for example, to proteolytically activate or inactivate proteins. Catalytic antibodies have great potential as therapeutic agents in human diseases such as rheumatoid arthritis, AIDS and Alzheimer's disease amongst many others.

WO 97/35887 PCT/AU97/00194 -2- Antibody therapy is already routinely used in patients. Antibodies have a half-life of about 23 days in the circulation of humans which is a clear advantage over other drugs. Catalytic antibodies, however, are considered to be even more effective. They are recycled after their antigenic encounter and are not bound to the antigen as occurs with "classical" antibodies.

Catalytic antibodies should, therefore, function at a much lower dose than classical antibodies and could be used at sub-immunogenic doses. Catalytic antibodies would be particularly useful in long term therapy.

Traditionally, catalytic antibodies have been generated by immunising mice with transition state analogs. Such antibodies have been shown to catalyse several chemical reactions. However, this approach has a severe limitation in that it is difficult to predict the structure of transition state analogs which effect proteolysis of specific proteins. Immunising a mouse with a transition state analog is by definition inefficient since it selects B cells on the ability of surface immunoglobulins to bind the analogs and not on the catalytic activity of the surface immunoglobulins. This is one of the reasons why catalytic antibodies have relatively low turnover rates and cannot compete with the naturally occurring enzyme counterparts. As a consequence, catalytic antibodies have not previously achieved prominence as therapeutic or diagnostic tools.

There is a need, therefore, to develop a more efficacious approach to generating catalytic antibodies having desired catalytic specificity. In accordance with the present invention, the inventors have developed such an approach based on a recombinant or a synthetic growth factor having an ability to induce B cell mitogenesis. A precursor form of the growth factor selects "catalytic" B cells. The present invention provides, therefore, for the exploitation of the products of catalysis for B cell activation which may and can be antigen binding site independent.

Accordingly, one aspect of the present invention is directed to a recombinant or synthetic growth factor or a precursor thereof comprising a B cell surface molecule binding portion wherein said growth factor or a catalytic product of said precursor is capable of inducing B cell WO 97/35887 PCT/AU97/00194 -3mitogenesis.

More particularly, the present invention provides a recombinant or synthetic growth factor comprising a B cell surface molecule binding portion wherein said growth factor induces B cell mitogenesis.

In one aspect of the present invention, the recombinant or synthetic growth factor comprises a B cell surface molecule binding portion and a portion providing T cell dependent help for a B cell such that said growth factor induces B cell mitogenesis.

In another aspect, the portion providing T cell dependent help for a B cell is supplied independently of the growth factor. An example of an exogenously supplied portion having T cell dependent help for a B cell is anti-CD40 antibodies or functional equivalents thereof.

In a particularly preferred embodiment, the B cell surface molecule binding portion comprises a B cell surface immunoglobulin binding portion although the present invention extends to a range ofB cell surface molecules the binding, interaction and/or cross-linking thereof leads to or facilitates B cell mitogenesis. Reference hereinafter to a "B cell surface molecule" includes reference to a B cell surface immunoglobulin. The portion providing T cell dependent help for a B cell is preferably but not exclusively a T cell epitope. Reference hereinafter to a portion providing T cell dependent help for a B cell includes a T cell epitope.

The present invention further contemplates a composition of matter capable of inducing B cell mitogenesis said composition of matter comprising components selected from: a recombinant or synthetic molecule comprising a B cell surface molecule binding portion; (ii) a recombinant or synthetic molecule in multimeric form comprising a B cell surface molecule binding surface molecule binding portion; (iii) a recombinant or synthetic molecule of or (ii) comprising a further portion providing WO 97/35887 PCT/AU97/00194 -4- T cell dependent help for a B cell; and (iv) separate compositions mixed prior to use or used sequentially or simultaneously comprising in a first composition a component having a B cell surface molecule binding portion and in a second composition a molecule capable of providing T cell dependent help for a B cell.

Preferably, the molecule capable of providing T cell dependent help for a B cell is a T cell epitope or is an anti-CD40 antibody or functional equivalents thereof.

Preferably, to ensure cross-linking of B cell surface molecules to induce blastogenesis, the growth factor comprises at least two B cell surface molecule binding portions. Alternatively, where the growth factor is present in multimeric form, the molecule may comprise a single B cell surface molecule binding portion.

Even more preferably, the growth factor comprises a T cell epitope portion flanked by, adjacent to or proximal with at least one B cell surface molecule-binding portion. The presentation of a T cell epitope on the surface of a B cell allows for B cell mitogenesis. The term "B cell mitogenesis" is used herein in its broadest context and includes B cell activation, clonal expansion, affinity maturation and/or antibody secretion as well as growth and differentiation.

The term "mitogenic" as used herein means "mitogenesis".

In another embodiment, the recombinant or synthetic growth factor comprises a further portion permitting multimerisation of the growth factor. A multimer comprises two or more growth factor molecules or a precursor thereof. Examples of portions inducing multimerisation include but are not limited to an antibody, a region facilitating formation of cross-linked molecules or a signal peptide. Cross-linkage in this context includes any interaction that provides bonding adequate to lead to multimer formation including but not limited to covalent linkage, ionic linkage, lattice association, ionic bridges, salt bridges and non-specific molecular association.

A particularly preferred embodiment of the present invention is directed to the use of a signal peptide such as the signal peptide of the Outer Membrane Portion A (ompA) [Skerra, Gene, WO 97/35887 PCT/AU97/00194 151: 131-135, 1994] or a functional derivative thereof. A "functional derivative" in this context is a mutant or derivative of the ompA signal peptide (or its functional equivalent) which still permits multimer formation of the growth factor.

In a preferred embodiment, where the B cell surface molecule is an immunoglobulin, the B cell surface binding portion of the growth factor generally binds to part of an immunoglobulin such as the variable portion of a heavy or light chain of an immunoglobulin.

An example of an immunoglobulin binding molecule is protein L from Peptostreptococcus magnus. Protein L has five immunoglobulin-binding domains. Other immunoglobulin binding molecules include protein A, protein G and protein H. The present invention, however, extends to any molecule capable of binding to a B cell surface component including, for example, a ligand of a B cell receptor.

The portion of the recombinant or synthetic molecule defining a T cell epitope is presented to a preferably already primed T cell to induce B cell proliferation and affinity maturation of an antibody in the germinal centre. This is generally accompanied by immunoglobulin class switching and antibody secretion into the serum. Generally, the T cell epitope is internalised within the B cell and presented on major histocompatibility complex (MHC) class II.

In a particularly preferred embodiment, the T cell epitope is from hen egg lysozyme (HEL) [Altuvia et al, Molecular Immunology, 31: 1-19, 1994] or is a derivative thereof such as a peptide comprising amino acids 42 to 62 from HEL or a homologue or analog thereof. This T cell epitope is recognised by the T cell receptor (TCR) of HEL specific T cells when presented by an antigen presenting cell (APC) on the MHC class II molecule H-2AK in mice or other MHC class II molecules or their equivalents in other mammals such as humans.

Examples of other T cell epitopes include but are not limited to tetanus toxoid, ovalbumin, malarial antigens as well as other regions of HEL. One skilled in the art would readily be able to select an appropriate T cell epitope.

WO 97/35887 PCT/AU97/00194 -6- In an alternative embodiment, the portion providing T cell dependent help of a B cell is not a T cell epitope in the classical sense but is nevertheless able to function in a similar manner. An example of such a portion is an anti-CD40 antibody.

Another aspect of the present invention contemplates a recombinant or synthetic molecule having the structure: Xi X2 X 3 wherein: X, and X, may be the same or different and each is a B cell surface molecule binding entity;

X

2 is a portion providing T cell dependent help for a B cell; and wherein the recombinant or synthetic molecule is capable of inducing T cell dependent B cell mitogenesis of the B cell which X, and X, bind.

The representation X, X 2

X

3 is not to be taken as imposing any sequential constraints and the present invention covers any sequence comprising the elements X, X 2

X

3 such as X X X 2

X

3

X

2

X

1

X

2

X

3 x, X, X 3 and X 3 Xi X 2 The present invention further provides a recombinant or synthetic molecule having the structure: X, X2 X 3 wherein: X, and X 3 may be the same or different and each is a B cell surface immunoglobulin binding entity;

X

2 is a T cell epitope; and wherein the recombinant or synthetic molecule is capable of inducing T cell dependent B cell mitogenesis of the B cell to which Xi and X 3 bind.

The present invention yet further provides a recombinant or synthetic molecule having the structure: WO 97/35887 PCT/AU97/00194 -7-

MXI[X

2 ]b wherein: X, is a B cell surface molecule binding entity such as a B cell surface immunoglobulin binding entity;

X

2 is a portion providing T cell dependent help for a B cell; M is a portion enabling or facilitating multimer formation of the recombinant or synthetic molecule; and b represents the number of X, molecules and may be 0, 1 or >1.

An example of M is a signal peptide such as from ompA. The multimeric effect of M is to provide a molecule [MXiX 2 ]blk where M, X, and b are as defined above and k is 1 or >1.

An example of k is from about 2 to about 1000 and more preferably from above >1 to about 50-200.

The optional nature of X 2 may alternatively relate to The molecular components of MXI[X2]b may be in any order.

Preferably, but not exclusively Xi is derived from the L protein from P. magnus.

Preferably, X 2 is a T cell epitope derived from HEL such as but not limited to amino acids 42 to 62 from HEL. In an alternative embodiment, where b=0 X 2 is not a T cell epitope and is exogenously supplied facilitating T cell dependent help for a B cell. In this case, X 2 may be, for example, an anti-CD40 antibody.

In a particularly preferred embodiment, X, X 2 X4 as defined above is referred to herein as "LHL" where L is an immunoglobulin binding entity from L protein from P. magnus and H corresponds to amino acids 42 to 62 from HEL or an equivalent thereof. The nucleotide and amino acid sequences of LHL are shown in SEQ ID NO:1 and SEQ ID NO:2, respectively.

WO 97/35887 PCT/AU97/00194 -8- The present invention extends to a growth factor or precursor thereof having the amino acid sequence set forth in SEQ ID NO:2 or an amino acid sequence having at least 60% similarity thereto (excluding the amino acid sequence of an antigen) or an amino acid sequence encoded by nucleotide sequence set forth in SEQ ID NO:1 or a nucleotide sequence capable of hybridizing to SEQ ID NO: 1 under low stringency conditions.

Reference herein to a low stringency at 42*C includes and encompasses from at least about 1% v/v to at least about 15% v/v formamide and from at least about 1M to at least about 2M salt for hybridisation, and at least about 1M to at least about 2M salt for washing conditions.

Alternative stringency conditions may be applied where necessary, such as medium stringency, which includes and encompasses from at least about 16% v/v to at least about 30% v/v formamide and from at least about 0.5M to at least about 0.9M salt for hybridisation, and at least about 0.5M to at least about 0.9M salt for washing conditions, or high stringency, which includes and encompasses from at least about 31% v/v to at least about 50% v/v formamide and from at least about 0.01M to at least about 0.15M salt for hybridisation, and at least about 0.01M to at least about 0.15M salt for washing conditions.

The two domains from protein L linked by the domain from HEL build the growth factor LHL which crosslinks the surface immunoglobulin on B cells. This cross-linking induces B cell activation and blast formation. The internalisation and processing of LHL leads to the presentation of H on MHC II. T cell recognition of MHC II with the H peptide signals the .activated B cell to proliferate and undergo antibody class switching and secretion.

The mitogenic growth factor of the present invention is most useful in generating antibodies of desired catalytic specificity when in a precursor form which selects "catalytic" B cells. A precursor growth factor comprises a target antigen to which a catalytic antibody is sought and which mask antigen-independent clonal expansion of B cells. Upon cleavage of the antigen by a selected B cell surface immunoglobulin, the growth factor can induce B cell mitogenesis.

In effect, then B cells are selected on the catalytic activity of their surface immunoglobulin WO 97/35887 PCT/AU97/00194 -9rather than on their binding to a transition state analog. This allows for affinity maturation in the germinal centres and ensures "catalytic-maturation" to obtain the highest enzymatic turnover rate possible in vivo. This aspect of the present invention is achieved by designing a B cell growth factor precursor comprising Xi X 2 X as defined above, such as LHL, shielded and substantially inactive until released through cleavage by a catalytic antibody on a B cell surface.

The term "cleavage" in this context is not limiting to the breaking of bonds but includes interaction adequate to remove or reduce shielding of the B cell growth factor.

The liberated X, X 2

X

3 activates the catalytic B cell by crosslinking the B cell surface molecules such B cell surface immunoglobulins via the X, X 3 domains. X, X 2

X

3 is then internalised and processed analogous to a normal antigen. Intracellular processing generates the T cell epitope X, incorporated in Xi X, X 3 The presentation of X, on the B cell surface leads to T cell dependent clonal expansion of the B cell as well as catalytic maturation and secretion of the catalytic antibody. The catalytic antibodies can then be detected in serum and catalytic B cells can be recovered by standard techniques.

According to this aspect of the present invention, there is provided a recombinant or synthetic growth factor precursor comprising an antigen linked or otherwise associated with a growth factor capable of inducing B cell mitogenesis, wherein the products of catalysis of said growth factor precursor permit B cell mitogenesis which may and can be antigen binding site independent.

According to another aspect of the present invention, there is provided a recombinant or synthetic growth factor precursor comprising an antigen linked to or otherwise associated with a B cell surface binding molecule portion and a portion providing T cell dependent help to a B cell such that upon cleavage of said antigen or of a region proximal to said antigen, said B cell surface molecule portion and said T cell dependent help portion form a growth factor which induces B cell mitogenesis.

Preferably, the present invention is directed to a recombinant or synthetic growth factor WO 97/35887 PCT/AU97/00194 precursor comprising an antigen linked to or otherwise associated with a B cell surface immunoglobulin binding portion and a T cell epitope portion such that upon cleavage of said antigen or of a region proximal to said antigen, said B cell surface immunoglobulin and T cell epitope form a growth factor having B cell mitogenic properties.

In an alternative embodiment, the present invention provides a recombinant or synthetic growth factor precursor comprising an antigen linked to or otherwise associated with a B cell surface molecule binding portion and a portion conferring a multimeric form of said growth factor precursor when cleavage of said antigen or of a region proximal to said antigen provides a growth factor comprising a B cell surface molecule binding portion having the ability to induce B cell mitogenesis.

The antigen according to this aspect of the present invention is any antigen to which a catalytic antibody is sought. Examples include cytokines such as but not limited to tumor necrosis factor (TNF), an interleukin (IL) such as IL-1 to IL-15, interferons (IFN) such as IFNa, IFNi or IFNy, colony-stimulating factors (CSF) such as granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophase colony-stimulation factor (GM-CSF), blood factors such as Factor VIII, erythropoietin and haemopoietin, cancer antigens, docking receptors from pathogenic viruses such as HIV, influenza virus or a hepatitis virus (eg. HEP A, HEP B, HEP C or HEP E) and amyloid plaques such as in Alzheimer's disease patients or myeloma patients. More particularly, in the case of TNF, proteolytic inactivation of TNF would be useful in the treatment of rheumatoid arthritis and toxic shock syndrome. By targeting viral docking receptors, pathogenic viruses such as HIV, hepatitis viruses and influenza viruses are rendered effectively inactive. Catalytic antibodies will also be useful in the clearance of amyloid plaques in Alzheimer's disease or myeloma disease patients. Targeting IgE, for example, may provide a mechanism for treating inflammatory conditions such as asthma.

The catalytic antibodies of the present invention may also be useful in detoxifying drugs such as drugs consumed by an individual. For example, the effects of cannabis or heroin or other drugs could be treated in an individual by the administration of catalytic antibodies directed to WO 97/35887 PCT/AU97/00194 -11the active components of those drugs. Furthermore, catalytic antibodies may be useful in the treatment of autoimmune and inflammatory disease conditions such as by targeting autoimmune antibodies. Catalytic antibodies also have a use in environmental situations and could be directed to environmental pollutants such as petroleum products and plastics. In all these situations, suitable antigens would be selected and incorporated into the growth factor precursor of the present invention.

In a related aspect of the present invention, the "antigen" portion of the growth factor precursor can be mimiced by a target site such as an amino acid linker sequence comprising a protease cleavage site. Examples include an amino acid linker sequence comprising the tabacco etch virus (TEV) protease cleavage site. More particularly, in the case of a TEV protease cleavage site, cleaving of the amino acid linker sequence by the TEV protease would be useful for producing characteristics similar to those of a catalytic antibody. This provides a useful model system for developing growth factor molecules.

Another aspect of the present invention provides a recombinant or synthetic molecule having the structure: A X X 2 X3 A wherein A is a target antigen for which a catalytic antibody is sought; X, and X 3 may be the same or different and each is a B cell surface molecule binding entity;

X

2 is a portion providing T cell dependent help for a catalytic B cell; wherein a catalytic antibody on the surface of said B cell is capable of cleaving all or part of A from said recombinant or synthetic molecule resulting in the molecule X, X 2

X

3 wherein A' is optionally present and is a portion of A after cleavage with the catalytic antibody and wherein said resulting molecule is capable of inducing T cell dependent clonal expansion of the B cell to which X, and X 3 bind.

The A X 1

X

2

X

3 A molecule may be in any sequence order.

WO 97/35887 PCT/AU97/00194 12- Anther aspect of the present invention is directed to a recombinant or synthetic molecule having the structure:

[X

2 ]d[X 3 ]A[M]f wherein: A is a target antigen for which a catalytic antibody is sought; X, and X 3 may be the same or different and each is a B cell surface molecule binding entity;

X

2 is a portion providing T cell dependent help for a B cell; M is a portion enabling or facilitating multimer formation of the recombinant or synthetic molecule; c and fmay be the same or different and each is 0, 1 or >1; e is 0 or 1 with the proviso then if both c and f are 0 then e cannot be 0; d is 0 or 1 or >1; wherein a catalytic antibody on the surface of said B cell is capable of cleaving all or a portion of A from said recombinant or synthetic molecule and a resulting catalytic product is capable of inducing B cell mitogenesis.

The growth factor precursor enables an antigen to be recognised by a B cell via a growth factor capable of inducing B cell mitogenesis. The antigen effectively masks B cell activation without prior catalytic activation. The growth factor is in "precursor" form, therefore, until cleavage of all or part of the antigen. A further masking may also be provided by molecules capable of binding to or otherwise associating with the B cell surface molecule binding domains of the B cell surface molecule binding portion. Examples of suitable masking molecules include but are not limited to the variable portion of a kappa or lambda light chain of an immunoglobulin.

Alternatively, a fragment comprising a variable heavy and light chain (Fv) may be employed which is preferably but not exclusively a single chain (sc) and/or disulfide stabilized The nucleotide and corresponding amino acid sequences for the variable portion of kappa light chain are shown in SEQ ID NO:10 and SEQ ID NO:11, respectively.

WO 97/35887 PCT/AU97/00194 -13- Notwithstanding that the above-mentioned immunoglobulin portions are useful molecules for blocking B cell surface immunoglobulin binding domains, other molecules may also be used.

i- For example, natural product screening would very readily identify molecules from natural sources such as coral, soil, plants, ocean beds, marine invertebrates or from other convenient sources which would bind to immunoglobulin binding domains of L protein or other B cell surface binding molecules.

In a particularly preferred embodiment, the recombinant or synthetic growth factor precursor substantially prevents binding of X, and X 3 to their cognate B cell surface molecules thereby preventing B cell activation by having immunoglobulin peptides or chemical equivalents thereof or other B cell surface molecule blocking reagents linked, fused or otherwise associated with the growth factor to facilitate masking of the B cell activating effects of the growth factor.

In a particularly preferred embodiment, the precursor comprises an antigen to which a catalytic antibody is sought and portions capable or masking the B cell surface molecule binding domains of the B cell surface molecule binding portion or the growth factor. The precursor may contain variable kappa or lambda light chain domains or an sc-ds-Fv molecule or masking molecules detected following natural product screening.

Generally, the immunoglobulin molecules which bind to the B cell surface immunoglobulin binding portion as a growth factor are linked to the N-terminal and C-terminal portions respectively of the antigen flanking the growth factor. For example, one particularly preferred embodiment of the present invention provides a growth factor precursor comprising the structure: I' A X X X 3 A I" wherein: I' and I" are optionally present and may be the same or different and each is a blocking reagent for X, and X 3 such as a kappa or lambda light chain or a sc-ds-Fv molecule; A is the target antigen for which a catalytic antibody is sought; X, and X 3 are B cell surface molecule binding entities; and X, is an entity providing T cell dependent help to a B cell.

WO 97/35887 PCT/AU97/00194 -14- Wherein a catalytic antibody on the surface of said B cell is capable of cleaving all or part of A from said recombinant or synthetic molecule resulting in the molecule X 2 X, wherein A' is optionally present and is a portion of A after cleavage with the catalytic antibody wherein said resulting molecule is capable of inducing T cell dependent B cell mitogenesis of the B cell to which X, and X 3 bind.

The molecular components of I'A X, X 2

X

3 A I" may be in any sequence order.

The present invention extends to X, and X, being any B cell surface molecule binding molecules and components I' and II" block or mask the binding of such molecules to the B cell surface molecules.

In another embodiment, the I' A X, X 2

X

3 A I" molecule or part thereof may be in multimeric form. This is particularly the case when all or part of the molecule includes a multimerisation component such as but not limited to the signal peptide of ompA. The monomeric units may be bound or otherwise associated together by any number of binding means such as contemplated above including covalent bonding, salt bridges, disulfide bridges and hydrophobic interactions amongst many others. Depending on the extent of multimerisation, this may impair the masking ability of B cell surface molecule binding domains of the growth factor and some antigen-independent clonal expansion may occur. This may not be too disadvantageous where there is at least some catalytic antibody dependent B cell mitogenesis.

According to this embodiment, there is provided a growth factor precursor comprising the structure: A X, [X 2 ']o[X 2

X

3 A I"]m wherein: I' and I" may be the same or different and each is a blocking reagent for X, and X 3 such as a kappa or lambda light chain or an sc-ds-Fv; A is the target antigen for which a catalytic antibody is sought;

X

1 and X 3 are B cell surface molecule binding entities; WO 97/35887 PCT/AU97/00194

X

2 and X 2 may be the same or different and each is an entity capable or providing T cell dependent help for a B cell; o may be 0 or 1; n indicates the multimeric nature of the component in parentheses and may be 0, 1 or >1; m indicates the multimeric nature of the component in parenthesis and may be 1 or >1.

Preferably, n and m are each from about 1 to about 10,000 more preferably from about 1 to about 1,000 and still more preferably from about 1 to about 200.

Preferably, if n is 0, then o is 1.

In alternative embodiments, the growth factor precursor comprises the structure A X XX 2 A I"]m or A X, [X 2 2 X A The exact number ascribed to n and m may not be ascertainable but the multimeric nature identified functionally or physically by size (eg. determined using HPLC or PAGE).

Examples of A include but are not limited to those hereinbefore described.

The present invention extends to the substitution of a non-antigen cleavage site such as a protease sensitive peptide which provides a useful model for designing growth factor molecules.

An exemplified growth factor precursor of the present invention is referred to herein as "CATAB" and comprises a TNF flanked LHL with the variable region from a kappa and/or lambda light chain further masking the B surface immunoglobulin binding domain of the L molecules.

In another embodiment, the growth factor precursor mimics a CATAB being activatable by means other than or in addition to a catalytic antibody. For example, an enzyme sensitive molecule may be the "antigen". In one embodiment, the CATAB mimic is referred to herein WO 97/35887 PCT/AU97/00194 -16as "TLHL" and comprises a variable kappa light chain linked to the N-terminus of an amino acid linker sequence comprising the TEV protease cleavage site which is in turn linked to LHL.

The nucleotide and amino acid sequences for TLHL are shown in SEQ ID NO:5 and SEQ ID NO:6. In another embodiment, the TLHL further comprises another amino acid linker sequence comprising the TEV protease cleavage site and a variable kappa light chain linked to the C-terminus of the latter amino acid linker sequence and is referred to herein as CATAB- TEV. The nucleotide sequence and corresponding amino acid sequence of CATAB is shown in SEQ ID NO:3 and SEQ ID NO:4, respectively.

The present invention extends to a growth factor precursor comprising a sequence of amino acids selected from: the amino acid sequence set forth in SEQ ID NO:4 or having at least 60% similarity thereto (excluding the amino acid sequence of an antigen); (ii) an amino acid sequence encoded by the nucleotide sequence set forth in SEQ ID NO:3 or a nucleotide sequence having at least 60% similarity to the nucleotide sequence set forth in SEQ ID NO:3; (iii) an amino acid sequence encoded by a nucleotide sequence capable of hybridizing to SEQ ID NO:3 under low stringency conditions wherein catalytic properties of said growth factor precursor are capable of inducing B cell mitogenesis.

The variable kappa light chain portions may conveniently be derived from the Bence Jones protein, LEN, which has been shown to bind to certain immunoglobulin binding proteins such as L. Alternatively, an Fv may be used such as a sc-ds-Fv.

Upon cleavage of the growth factor precursor CATAB by a catalytic antibody recognising the antigen (for example, a TNF peptide portion), the covalent linkage between the L domains and the variable kappa light chains is broken. The blocking variable kappa light chains will dissociate from the L domains due to the relatively low affinity (-10 of individual domains for each other. This will release the mature growth factor LHL which can bind to and crosslink the surface immunoglobulin with an affinity of 10-'M. A similar mechanism operates where WO 97/35887 PCT/AU97/00194 -17molecules other than variable kappa light chains, TNF, L and H are employed.

This B cell surface immunoglobulin crosslinking activates the B cell and induces the down stream events that lead to catalytic maturation and secretion of the catalytic antibody. Catalytic antibodies can be detected in the serum using any number of procedures such as ELISA based assays and catalytic B cells may be recovered with standard hybridoma technology. Where the catalytic antibodies are from non-human animals, these can be humanised by recombinant DNA technology and produced for therapeutical applications in humans. Alternatively, the antibodies may be generated in a "humanized" animal such as a humanized mouse which is transgenic for the human Ig loci.

The present invention contemplates derivatives of the growth factor and/or its precursor. A derivative includes a mutant, part, fragment, portion, homologue or analogue of the growth factor and/or precursor or any components thereof. Derivatives to amino acid sequences include single or multiple amino acid substitutions, deletions and/or additions. For example, derivatives of SEQ ID NO:2 or SEQ ID NO:4 include sequences having at least 60% similarity thereto (excluding amino acid sequence of antigen) or which are encoded by a nucleotide sequence capable of hybridizing in SEQ ID NO: 1 or SEQ ID NO:3 under low stringency conditions.

Particularly useful derivatives include chemical analogues of the growth factor and/or its precursor or components thereof. Such chemical analogues may be useful in stabilizing the molecule for therapeutic or diagnostic use.

Analogues of the growth factor precursor contemplated herein include, but are not limited to, modification to side chains, incorporating of unnatural amino acids and/or their derivatives during peptide, polypeptide or protein synthesis and the use of crosslinkers and other methods which impose conformational constraints on the proteinaceous molecule or their analogues.

Examples of side chain modifications contemplated by the present invention include WO 97/35887 PCT/AU97/00194 -18modifications of amino groups such as by reductive alkylation by reaction with an aldehyde followed by reduction with NaBH 4 amidination with methylacetimidate; acylation with acetic anhydride; carbamoylation of amino groups with cyanate; trinitrobenzylation of amino groups with 2, 4, 6-trinitrobenzene sulphonic acid (TNBS); acylation of amino groups with succinic anhydride and tetrahydrophthalic anhydride; and pyridoxylation of lysine with phosphate followed by reduction with NaBH 4 The guanidine group of arginine residues may be modified by the formation of heterocyclic condensation products with reagents such as 2,3-butanedione, phenylglyoxal and glyoxal.

The carboxyl group may be modified by carbodiimide activation via O-acylisourea formation followed by subsequent derivitisation, for example, to a corresponding amide.

Sulphydryl groups may be modified by methods such as carboxymethylation with iodoacetic acid or iodoacetamide; performic acid oxidation to cysteic acid; formation of a mixed disulphides with other thiol compounds; reaction with maleimide, maleic anhydride or other substituted maleimide; formation of mercurial derivatives using 4-chloromercuribenzoate, 4chloromercuriphenylsulphonic acid, phenylmercury chloride, 2 -chloromercuri-4-nitrophenol and other mercurials; carbamoylation with cyanate at alkaline pH.

Tryptophan residues may be modified by, for example, oxidation with N-bromosuccinimide or alkylation of the indole ring with 2 -hydroxy-5-nitrobenzyl bromide or sulphenyl halides.

Tyrosine residues on the other hand, may be altered by nitration with tetranitromethane to form a 3-nitrotyrosine derivative.

Modification of the imidazole ring of a histidine residue may be accomplished by alkylation with iodoacetic acid derivatives or N-carbethoxylation with diethylpyrocarbonate.

Examples of incorporating unnatural amino acids and derivatives during peptide synthesis include, but are not limited to, use of norleucine, 4 -amino butyric acid, 4-amino-3-hydroxy-5- WO 97/35887 PCT/AU97/00194 -19phenylpentanoic acid, 6-aminohexanoic acid, t-butylglycine, norvaline, phenylglycine, ornithine, sarcosine, 4-amino-3-hydroxy-6-methylheptanoic acid, 2-thienyl alanine and/or Disomers of amino acids. A list of unnatural amino acid, contemplated herein is shown in Table 1.

Crosslinkers can be used, for example, to stabilise 3D conformations, using homobifunctional crosslinkers such as the bifunctional imido esters having (CH2)n spacer groups with n=l to n=6, glutaraldehyde, N-hydroxysuccinimide esters and hetero-bifunctional reagents which usually contain an amino-reactive moiety such as N-hydroxysuccinimide and another group specific-reactive moiety such as maleimido or dithio moiety (SH) or carbodiimide (COOH). In addition, peptides can be conformationally constrained by, for example, incorporation of C, and N,-methylamino acids, introduction of double bonds between C, and CA atoms of amino acids and the formation of cyclic peptides or analogues by introducing covalent bonds such as forming an amide bond between the N and C termini, between two side chains or between a side chain and the N or C terminus.

The present invention further contemplates chemical analogues of the growth factor and/or its precursor capable of acting as antagonists or agonists of same. These may be useful in controlling the immunological response. Chemical analogues may not necessarily be derived from the growth factor precursor but may share certain conformational similarities.

Alternatively, chemical analogues may be specifically designed to mimic certain physiochemical properties of the growth factor precursor. Chemical analogues may be chemically synthesised or may be detected following, for example, natural product screening of, for example, coral, soil, plants, microorganisms, marine invertebrates or seabeds.

WO 97/35887 WO 9735887PCT/AU97/00194 TABLE 1 Non-conventional Code Non-conventional Code amino acid amino acid a-aminobutyric acid a-amino-ra-methylbutyrate aminocyclopropanecarboxylate aminoisobutyric acid aminonorbornylcarboxylate cyclohexylalanine cyclopentylalanine D-alanine D-arginine D-aspartic acid D-cysteine D-glutamnine D-glutamnic acid D-histidine D-isoleucine D-leucine D-lysine D-methionine D-omniffine D-phenylalanine D-proline D-serine D-threonine Abu Mgabu Cpro Aib Norb Cpen Dal Darg Dasp Dcys Dgln Dglu.

Dhis Dule Dieu Dlys Dmet Dom Dphe Dpro Dser Dthr L-N-methylalanine L-N-methylarginine L-N-methylasparagine L-N-methylaspartic acid L-N-methylcysteine L-N-methylglutamine L-N-methylglutamic acid Chexa L-N-methylhistidine L-N-methylisolleucine L-N-methylleucine L-N-methyllysine L-N-methylmethionine L-N-methylnorleucine L-N-methylnorvaline L-N-methylornifhine, L-N-methylphenylalanine L-N-methylproline L-N-methylserine L-N-methylthreonine L-N-methyltryptophan L-N-methyltyrosine L-N-methylvaline L-N-methylethylglycine L-N-methyl-t-butylglycine L-norleucine Nmala Nmarg Nmasn Nmasp Nmcys Nmgln Nmglu Nmhis Nmile Nmnleu Nmlys Nmnmet Nmnle Nmnnva Nmorn Nmphe Nmnpro Nmser Nmthr Nmntrp Nmntyr Nmval Nmetg Nmntbug NMe WO 97/35887 WO 9735887PCT/AU97/00194 -21 D-tryptophan D-tyrosine D-valine D-a-methylalanine D-a-methylarginine D-a-methylasparagine D-a-methylaspartate D-a-methylcysteine D-a-methylglutamine D-ra-methylhistidine D-a-methylisoleucine D-ea-methyl1eucine D-a-methy11ysine D-ix-methylmethionine D-a-methylornithine D-a-methylphenylalanine D-a-methylproline D-a-niethylserine D-a-niethylthreonine D-a-methyltryptophan D-a-methyltyrosine D-a-niethylvaline D-N-methylalanine D-N-methylarginine D-N-methylasparagine D-N-methylaspartate D-N-methvlcysteine D-N-methylglutamine D-N-methylglutamate D-N-methylbistidine Dtrp Dtyr Dval Dmala Dmarg Dmasn Dmasp Dmcys Dmgln Dmhis Dmile Dmleu Dmlys Dmmet Dmorn Dmphe Dmpro Dmser Dmthr Dmtrp Dmty Dmval Dnala Dnmarg Dnmasn Dnmasp Dnmcys Dnmgln Dnmglu Dnmhis L-norvaline a-methyl-amninoisobutyrate a-methyl-y-aminobutyrate a-methylcyclohexylalanine a-methylcylcopentylalanine a-methy1-ri-napthylaianine ra-methylpenici11amine N-(4-aminobutyl)glycine N-(2-aminoethyl)glycine N-(3-aminopropyl)glycine N-amino--methylbutyrate a-napthylalanine N-benzylglycine N-(2-carbamylethyl)glycine N-(carbamylmethyl)glycine N-(2-carboxyethyl)glycine N-(carboxymethyl)glycine N-cyclobutylglycine N-cycloheptylglycine N-cyclohexylglycine N-cyclodecylglycine N-cylcododecylglycine N-cyclooctylglycine N-cyclopropylglycine N-cycloundecylglycine N-(2,2-diphenylethyl)glycine N-(3 ,3-diphenylpropyl)glycine N-(3-guanidinopropyl)glycine 1-hydroxyethyl)glycine N-(hydroxyethyl))glycine Nva Maib Mgabu Mchexa Mcpen Manap Mpen Nglu Naeg Nomn Nmaabu Anap Nphe Ngln Nasn Nglu Nasp Ncbut Nchep Nchex Ncdec Ncdod Ncoct Ncpro Ncund Nbhm Nbhe Narg Nthr Nser WO 97/35887 WO 9735887PCT/AU97/00194 22 D-N-methylisoleucine D-N-methylieucine D-N-methyllysine N-methylcyclohexylalanine D-N-methylomithine N-methylglycine N-methylaminoisobutyrate 1-methylpropyl)glycine N-(2-methylpropyl)glycine D-N-methyltryptophan D-N-methyltyrosine D-N-methylvaline y-aminobutyric acid L-t-butylglycine L-eth ylglycine L-homophenylalanine L-a-methylargiine L-a-methylaspartate L-a-methylcysteine L-ca-methylglutamine L-a-methythistidine L-a-methylisoleucine L-a-methylleucine L-a-methylmetbionine L-a-methylnorvaline L-ca-methylphenylalanine L-a-methylserine L-rz-methyltryptophan L-a-methylvaline N-(N-(2,2-diphenylethyl) Dnmile Dnmleu Dnmlys Nmchexa Dnmorn Nala Nmaib Nile Nleu Dnmtrp Dnmtyr Dnmval Gabu Thug Etg Hphe Marg Masp Mcys Mgln Mhis Mile Mleu Mvmet Mnva Mphe Mser Mtrp Mval N-(imidazolylethyl))glycine N-(3-indolylyethyl)glycine N-methyl-y-aminobutyrate D-N-methylmethionine N-methylcyclopentylalanine D-N-methylphenylalanine D-N-methylproline D-N-methylserine D-N-methylthreonine 1-methyl ethyl)glycine N-methyla-napthylalanine N-inethylpenicillamine N-(p-hydroxyphenyl)glycine N-(thiomethyl)glycine penicillamine L-iz-methylalanine L-a-methylasparagine L-a-methyl-t-butylglycine L-methylethylglycine L-a-methylglutamate L-ei-methylhomophenylaianine N-(2-methylthioethyl)glycine L -a-methyllysine L-a-meffiylnorleucine L-a-methylornithine L-a-methylproline L-a-methylthreonine L-a-methyltyrosine L-N-methylhomophenytalanine Nhis Nhtrp Nmgabu Dnmmet Nmcpen Dnmphe Dnmpro Dnmser Dnmthr Nval Nmanap Nmpen Nhtyr Ncys Pen Mala Masn Mtbug Metg Mglu Mhphe Nmet Mlys Mnle Momn Mpro Mthr Mtyr Nmhphe Nnbhe Nnbhm 3 ,3-diphenylpropyl) WO 97/35887 PCT/AU97/00194 23 carbamylmethyl)glycine carbamylmethyl)glycine 1 -carboxy-1 -(2,2-diphenyl-Nmbc ethylamino)cyclopropane Other derivatives contemplated by the present invention include a range of glycosylation variants from a completely unglycosylated molecule to a modified glycosylated molecule.

Altered glycosylation patterns may result from expression of recombinant molecules in different host cells.

The growth factor and growth factor precursor of the present invention may be produced by recombinant DNA means or by chemical synthetic processes. With respect to the former this aspect of the present invention provides a nucleic acid molecule comprising a sequence of nucleotides encoding a B cell immunoglobulin binding peptide or polypeptide and a T cell epitope.

Generally, the nucleic acid molecule encodes a fusion molecule comprising a B cell immunoglobulin binding peptide or polypeptide and a T cell epitope. In this regard, the nucleic acid molecule would generally comprise a promoter region with the B cell immunoglobulin binding peptide or polypeptide encoding portion operably linked thereto and the T cell epitope portion operably linked to the 3' end thereof. Expression of the nucleic acid molecule of the present invention leads to synthesis of a fusion molecule. In a preferred embodiment, the nucleic acid molecule further encodes an antigenic portion and optionally an immunoglobulin portion such as a variable kappa light chain. In some circumstances, purification of one or more recombinant components results in all or a portion of the signal peptide for the ompA or other carrier molecule for the microbial host in which the recombinant molecule is made. This may facilitate multimerisation. In a particularly preferred embodiment of the present invention, the nucleic acid molecule comprises the nucleotide sequence set forth in SEQ ID NO: 1 or SEQ ID NO:3 or is a sequence capable of hybridizing thereto under low stringency conditions wherein said nucleotide sequence encodes WO 97/35887 PCT/AU97/00194 -24 a growth factor precursor as hereinbefore described.

Still a further aspect of the present invention extends to a method for producing catalytic antibodies to a specific antigen, said method comprising administering to an animal an effective amount of a growth factor precursor comprising an antigen capable of interacting with a B cell bound catalytic antibody said antigen linked to or otherwise associate with a B cell surface molecule binding portion and a portion capable of providing T cell dependent help to a B cell. The growth factor precursor may also comprise a B cell surface molecule binding portion masking entity such as a variable kappa light chain linked to the antigen.

Alternatively, the growth factor precursor may comprise a B cell surface molecule binding portion in multimeric form linked to an antigen for which a target antibody is sought. The portion providing T cell dependent help is preferably a T cell epitope and is preferably part of the precursor. However, it may be a separate entity administered simultaneously or sequentially to an animal.

The present invention also provides catalytic antibodies produced by the above method. The catalytic antibodies are in effect specific to or directed against A of the above formulae. Such catalytic antibodies, therefore, may be directed to any antigen such as but not limited to a cytokine such as but not limited to tumor necrosis factor (TNF), an interleukin (IL) such as IL-1 to IL-15, interferons (IFN) such as IFNa, IFN3 or IFNy, colony-stimulating factors (CSF) such as granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophase colony-stimulation factor (GM-CSF), blood factors such as Factor VIII, erythropoietin and haemopoietin, cancer antigens, docking receptors from pathogenic viruses such as HIV, influenza virus or a hepatitis virus (eg. HEP A, HEP B, HEP C or HEP E) and amyloid plaques such as in Alzheimer's disease patients or myeloma patients.

The catalytic antibodies of the present invention have particular therapeutic and diagnostic uses especially in relation to mammalian and more particularly human disease conditions.

WO 97/35887 PCT/AU97/00194 25 Accordingly, the present invention contemplates a pharmaceutical composition comprising a growth factor precursor or a derivative thereof and optionally a modulator of growth factor precursor activity and one or more pharmaceutically acceptable carriers and/or diluents. More particularly, the pharmaceutical composition comprises catalytic antibodies generated by the growth factor precursor of the present invention. These components are hereinafter referred to as the "active ingredients".

The pharmaceutical forms suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion or may be in the form of a cream or other form suitable for topical application. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils. The proper fluidity can be maintained, for example, by the use of a coating such as licithin, by the maintenance of the required particle size in the case of dispersion and by the use of superfactants. The preventions of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thirmerosal and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride.

Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions are prepared by incorporating the active compounds in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredient into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and the freeze-drying technique which yield a WO 97/35887 PCT/AU97/00194 -26powder of the active ingredient plus any additional desired ingredient from previously sterile-filtered solution thereof.

When the active ingredients are suitably protected they may be orally administered, for example, with an inert diluent or with an assimilable edible carrier, or it may be enclosed in hard or soft shell gelatin capsule, or it may be compressed into tablets, or it may be incorporated directly with the food of the diet. For oral therapeutic administration, the active compound may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. Such compositions and preparations should contain at least 1% by weight of active compound. The percentage of the compositions and preparations may, of course, be varied and may conveniently be between about 5 to about 80% of the weight of the unit. The amount of active compound in such therapeutically useful compositions in such that a suitable dosage will be obtained. Preferred compositions or preparations according to the present invention are prepared so that an oral dosage unit form contains between about 0.1 ng and 2000 mg of active compound, preferably between about 0.1 jig and 1500 mg and more preferably between about Ijsg and 100 mg.

The tablets, troches, pills, capsules and the like may also contain the components as listed hereafter: a binder such as gum, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such a sucrose, lactose or saccharin may be added or a flavouring agent such as peppermint oil of wintergreen, or cherry flavouring. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets, pills, or capsules may be coated with shellac, sugar or both. A syrup or elixir may contain the active compound, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavouring such as cherry, orange or mango. Of course, any material used in preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts WO 97/35887 PCT/AU97/00194 -27employed. In addition, the active compound(s) may be incorporated into sustained-release preparations and formulations.

The present invention also extends to forms suitable for topical application such as creams, lotions and gels.

Pharmaceutically acceptable carriers and/or diluents include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, use thereof in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions. These may include immune potentiating molecules, multimer facilitating molecules and pharmaceutically active molecules chosen on the disease conditions being treated.

It is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the mammalian subjects to be treated; each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the novel dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active material and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active material for the treatment of disease in living subjects having a diseased condition in which bodily health is impaired as herein disclosed in detail.

The principal active ingredient is compounded for convenient and effective administration in effective amounts with a suitable pharmaceutically acceptable carrier in dosage unit form as hereinbefore disclosed. A unit dosage form can, for example, contain the principal active compound in amounts ranging from 0.1 ng to about 2000 mg, more preferably ranging from WO 97/35887 PCT/AU97/00194 -28- 0.1 and 1500 mg and even more preferably ranging between 1 yg and 1000 mg. Expressed in proportions, the active compound is generally present in from about 0.5 Pg to about 2000 mg/ml of carrier. In the case of compositions containing supplementary active ingredients, the dosages are determined by reference to the usual dose and manner of administration of the said ingredients.

Still another aspect of the present invention is directed to antibodies to the growth factor precursor and its derivatives. Such antibodies may be monoclonal or polyclonal and are independent to the catalytic antibodies selected by the precursor. The (non-catalytic) antibodies to recombinant or synthetic the growth factor precursor or its derivatives of the present invention may be useful as therapeutic agents but are particularly useful as diagnostic agents. Antibodies may also be generated to the catalytic antibodies generated by the growth factor precursors. All these antibodies have particular application in diagnostic assays for the growth factor or catalytic antibody inducer thereof.

For example, specific antibodies can be used to screen for catalytic antibodies. The latter would be important, for example, as a means for screening for levels of these antibodies in a biological fluid or for purifying the catalytic antibodies. Techniques for the assays contemplated herein are known in the art and include, for example, sandwich assays and

ELISA.

It is within the scope of this invention to include any second antibodies (monoclonal, polyclonal or fragments of antibodies or synthetic antibodies) directed to the antibodies discussed above. Both the first and second antibodies may be used in detection assays or a first antibody may be used with a commercially available anti-immunoglobulin antibody.

Both polyclonal and monoclonal antibodies are obtainable by immunization with the enzyme or protein and either type is utilizable for immunoassays. The methods of obtaining both types of sera are well known in the art. Polyclonal sera are less preferred but are relatively easily prepared by injection of a suitable laboratory animal with an effective amount of antigen, or WO 97/35887 PCT/AU97/00194 -29antigenic parts thereof, collecting serum from the animal, and isolating specific sera by any of the known immunoadsorbent techniques. Although antibodies produced by this method are utilizable in virtually any type of immunoassay, they are generally less favoured because of the potential heterogeneity of the product.

The use of monoclonal antibodies in an immunoassay is particularly preferred because of the ability to produce them in large quantities and the homogeneity of the product. The preparation of hybridoma cell lines for monoclonal antibody production derived by fusing an immortal cell line and lymphocytes sensitized against the immunogenic preparation can be done by techniques which are well known to those who are skilled in the art.

Another aspect of the present invention contemplates a method for detecting an antigen in a biological sample from a subject said method comprising contacting said biological sample with an antibody specific for said antigen or its derivatives or homologues for a time and under conditions sufficient for an antibody-antigen complex to form, and then detecting said complex. In this context, the "antigen" may be a growth factor, its precursor, a component thereof or a catalytic antibody induced thereby.

The presence of antigen may be accomplished in a number of ways such as by Western blotting and ELISA procedures. A wide range of immunoassay techniques are available as can be seen by reference to US Patent Nos. 4,016,043, 4, 424,279 and 4,018,653. These, of course, includes both single-site and two-site or "sandwich" assays of the non-competitive types, as well as in the traditional competitive binding assays. These assays also include direct binding of a labelled antibody to a target.

Sandwich assays are among the most useful and commonly used assays and are favoured for use in the present invention. A number of variations of the sandwich assay technique exist, and all are intended to be encompassed by the present invention. Briefly, in a typical forward assay, an unlabelled antibody is immobilized on a solid substrate and the sample to be tested brought into contact with the bound molecule. After a suitable period of incubation, for a WO 97/35887 PCT/AU97/00194 period of time sufficient to allow formation of an antibody-antigen complex, a second antibody specific to the antigen, labelled with a reporter molecule capable of producing a detectable signal is then added and incubated, allowing time sufficient for the formation of another complex of antibody-antigen-labelled antibody. Any unreacted material is washed away, and the presence of the antigen is determined by observation of a signal produced by the reporter molecule. The results may either be qualitative, by simple observation of the visible signal, or may be quantitated by comparing with a control sample containing known amounts of hapten. Variations on the forward assay include a simultaneous assay, in which both sample and labelled antibody are added simultaneously to the bound antibody. These techniques are well known to those skilled in the art, including any minor variations as will be readily apparent. In accordance with the present invention the sample is one which might contain an antigen including cell extract, supernatant fluid, tissue biopsy or possibly serum, saliva, mucosal secretions, lymph, tissue fluid and respiratory fluid. The sample is, therefore, generally a biological sample comprising biological fluid but also extends to fermentation fluid and supernatant fluid such as from a cell culture.

In the typical forward sandwich assay, a first antibody having specificity for the antigen or antigenic parts thereof, is either covalently or passively bound to a solid surface. The solid surface is typically glass or a polymer, the most commonly used polymers being cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride or polypropylene. The solid supports may be in the form of tubes, beads, discs of. microplates, or any other surface suitable for conducting an immunoassay. The binding processes are well-known in the art and generally consist of cross-linking covalently binding or physically adsorbing, the polymer-antibody complex is washed in preparation for the test sample. An aliquot of the sample to be tested is then added to the solid phase complex and incubated for a period of time sufficient 2minutes) and under suitable conditions 25 to allow binding of any subunit present in the antibody. Following the incubation period, the antibody subunit solid phase is washed and dried and incubated with a second antibody specific for a portion of the hapten. The second antibody is linked to a reporter molecule which is used to indicate the binding of the second antibody to the hapten.

WO 97/35887 PCT/AU97/00194 -31- An alternative method involves immobilizing the target molecules in the biological sample and then exposing the immobilized target to specific antibody which may or may not be labelled with a reporter molecule. Depending on the amount of target and the strength of the reporter molecule signal, a bound target may be detectable by direct labelling with the antibody.

Alternatively, a second labelled antibody, specific to the first antibody is exposed to the targetfirst antibody complex to form a target-first antibody-second antibody tertiary complex. The complex is detected by the signal emitted by the reporter molecule.

By "reporter molecule" as used in the present specification, is meant a molecule which, by its chemical nature, provides an analytically identifiable signal which allows the detection of antigen-bound antibody. Detection may be either qualitative or quantitative. The most commonly used reporter molecules in this type of assay are either enzymes, fluorophores or radionuclide containing molecules radioisotopes) and chemiluminescent molecules.

In the case of an enzyme immunoassay, an enzyme is conjugated to the second antibody, generally by means of glutaraldehyde or periodate. As will be readily recognized, however, a wide variety of different conjugation techniques exist, which are readily available to the skilled artisan. Commonly used enzymes include horseradish peroxidase, glucose oxidase, beta-galactosidase and alkaline phosphatase, amongst others. The substrates to be used with the specific enzymes are generally chosen for the production, upon hydrolysis by the corresponding enzyme, of a detectable colour change. Examples of suitable enzymes include alkaline phosphatase and peroxidase. It is also possible to employ fluorogenic substrates, which yield a fluorescent product rather than the chromogenic substrates noted above. In all cases, the enzyme-labelled antibody is added to the first antibody hapten complex, allowed to bind, and then the excess reagent is washed away. A solution containing the appropriate substrate is then added to the complex of antibody-antigen-antibody. The substrate will react with the enzyme linked to the second antibody, giving a qualitative visual signal, which may be further quantitated, usually spectrophotometrically, to give an indication of the amount of hapten which was present in the sample. "Reporter molecule" also extends to use of cell agglutination or inhibition of agglutination such as red blood cells on latex beads, and the like.

WO 97/35887 PCT/AU97/00194 32 Alternately, fluorescent compounds, such as fluorescein and rhodamine, may be chemically coupled to antibodies without altering their binding capacity. When activated by illumination with light of a particular wavelength, the fluorochrome-labelled antibody adsorbs the light energy, inducing a state to excitability in the molecule, followed by emission of the light at a characteristic colour visually detectable with a light microscope. As in the EIA, the fluorescent labelled antibody is allowed to bind to the first antibody-hapten complex. After washing off the unbound reagent, the remaining tertiary complex is then exposed to the light of the appropriate wavelength the fluorescence observed indicates the presence of the hapten of interest. Immunofluorescene and EIA techniques are both very well established in the art and are particularly preferred for the present method. However, other reporter molecules, such as radioisotope, chemiluminescent or bioluminescent molecules, may also be employed.

The present invention may use any number of means to clone genetic sequences encoding catalytic antibodies. For example, a phage display library potentially capable of expressing a catalytic antibody on the phage surface may be used to screen for catalysis of defined antigens.

The present invention further contemplates the use of the products of catalysis of a growth factor precursor to induce B cell mitogenesis to generate catalytic antibodies to a specific antigen.

More particularly, the present invention contemplates the use of a growth factor precursor comprising an antigen to which a catalytic antibody is sought linked, fused or otherwise associated to a B cell surface molecule binding portion in the induction of B cell mitogenesis following catalytic cleavage of all or part of said antigen.

Still another embodiment of the present invention contemplates the use of an antigen linked, fused or otherwise associate to a B cell surface molecule binding portion in the manufacture of a growth factor precursor to induce B cell mitogenesis following catalytic cleavage of all or part of said antigen.

WO 97/35887 PCT/AU97/00194 -33- The present invention is further described by the following non-limiting figures and/or examples.

In the figures: Figure 1 is a schematic representation of the three overlapping synthetic oligonucleotides used to generate a genetic construct encoding LHL.

Figure 2 is a photographic representation of LHL in a bacterial lysate after purification on a human IgG (hulgG) affinity column. First lane, uninduced; second lane, induced LHL sample; right lane, purified LHL with size of approximately 18 kDa.

Figure 3 is a schematic representation of LHL.seq carrying two affinity tags.

Figure 4 is a photographic representation showing an LHL.seq expression and purification analysed on a 20% w/v polyacrylamide SDS silver stained PHAST-gel. L=recombinant DHO1B lysate after o/n induction of LHL.seq expression; S-streptavidin purified LHL.seq protein; H-hulgG purified LHL.seq protein; e-eluted with Img/ml diaminobiotin, PBS or with 100mM glycine pH2.0 b-elution of LHL.seq via boiling in loading buffer.

Purifications were performed in 1.5ml eppendorf tubes at RT. 501l lysate was incubated with column matrix for 15min. Column material was then washed twice with 5001l PBS, v/v Triton X-100 before eluting with 501l solution or boiling as described. Elution of LHL.seq from hulgG matrix is very inefficient in this particular set up although it is the most effective and preferred way when washing on a larger scale affinity column.

Figure 5 is a graphical representation showing mitogenic activity of LHL on B cells. M, medium; LPS, lipopolysaccharide; Ab, anti-IgM antibody; C, induced "empty" expression vector and LHL. Y axis percentage of B cells expressing B7.2 after overnight incubation of mesenteric lymphnode cells with substance shown on X axis.

WO 97/35887 PCT/AU97/00194 34 Figure 6 is a graphical representation as for Figure 5 with the hatched bars showing the experiment in the presence of human IgG at 500 ig/ml.

Figure 7 is a graphical representation showing 3 H-thymidine incorporation during DNA synthesis (CPM) of the IL-2-dependent CTLL incubated with supernatant of co-cultures as listed below. Splenocytes or mesenteric lymphocytes are co-cultured with T cell hybridoma 3A9 in the presence of M, medium; HEL, hen egg lysozyme; and LHL. The hatched bar for each of HEL and LHL is the same experiment in the presence of human IgG (HulgG).

Figure 8 is a schematic representation of the kappa variable light chain and its two affinity tags.

Figure 9 is a photographic representation showing kappa expression analysed on a 20% w/v polyacrylamide SDS PHAST-gel after silver staining. L-total lysate of two different recombinant DH1OB clones induced to express kappa; T=pellet after periplasmic fractionation; P=periplasmic fraction with kappa protein.

Figure 10 is a photographic representation showing purified kappa protein on a 20% w/v polyacrylamide SDS PHAST-gel after silver staining. w=periplasmic fraction after incubation with column material; e=eluates using 500mM EDTA in case of the Ca" dependent anti- Flag affinity column or 50mM diaminobiotin in case of the streptavidin column; b=eluates from and derived by boiling in loading buffer.

Figure 11 is a photographic representation of LHL purified via kappa-loaded streptavidin column as shown on a silver stained 20% w/v polyacrylamide SDS PHAST-gel. LHL=LHL alone plus streptavidin matrix; LHL-kappa=LHL purified on the kappa-loaded streptavidin matrix; kappa=kappa alone bound to streptavidin matrix.

Figure 12 is a schematic representation of the CATAB precursor TLHL.

WO 97/35887 PCT/AU97/00194 Figure 13 is a photographic representation of a silver stained 20% w/v polyacrylamide SDS PHAST-gel analysis of purified TLHL from two different recombinant DH1OB clones.

L=total lysate; P=periplasmic fraction; e=eluted with 50mM diaminobiotin, b=eluted by boiling in loading buffer.

Figure 14 is a photographic representation of a silver stained 20% w/v polyacrylamide SDS PHAST-gel of TEV cleaved TLHL. Lane one=TLHL uncleaved; lane two=TLHL cleaved with 10 units of TEV; lane three and four=cleavage was performed in 201l instead of 10 1 volume as in lane one and two. The identity of the TEV protease band was confirmed in later experiments.

Figure 15 is a representation showing LHL.seq induced B cell activation: fsc, b7-1, b7-2 analysis by FACS. Mesenteric lymphnode cells from C3H/HeJ were stimulated in triplicate cultures at 3x0O/well. Upregulation of activation markers on B cells was monitored by gating on B220Thyl- cells to identify B cells. Results are expressed as FACS-histogramms, showing FSC and B7-1 and B7-2 staining levels. Grey lines indicate background staining from cells incubated in medium alone and black lines show individual results. Anti IgM and anti kappa were included as positive controls and LPS as a negative control.

Figure 16 is a representation showing LHL.seq induced B cell activation: FSC, MHC Class II analysis by FACS. FACS-Analysis was performed as described above. Grey lines indicate background staining from cells incubated in medium alone and black lines show individual results. Anti IgM is positive control and LHL.seq plus hulgG as a control.

Figure 17 is a representation showing LHL.seq induced B cell activation: dose-response analysis in proliferation assays. Mesenteric lymphnode cells from C3H/HeJ (upper panel) and splenocytes from CBA/J mice (lower panel) were prepared as described above. The lymphocytes were stimulated in triplicate cultures at Ixl0S/well in flat bottom 96-well plates in complete RPMI 10% FCS medium at 37*C for 2 days. Cells are pulsed for the last 6 hours with 'H-thymidine. DNA was harvested onto glassfibre filters and incorporation of 3

H-

WO 97/35887 PCT/AU97/00194 -36thymidine was measured in a P-counter. Results are expressed as mean of triplicate cultures including standard deviation.

Figure 18 is a representation showing TLHL induced B cell activation: analysis FACS.

Mesenteric lymph node cells from C3H/HeJ mice were centrifuged in Nycodenz (1.091 g/cm 3 followed by 1 hour adherence on plastic at 37C. Lymphocytes were stimulated at 3x10 5 cells per well with LPS, anti-IgM antibodies, LHL.seq, TLHL and TEV-cleaved TLHL. On day 1 of culture cells were stained for B7-1 and B7-2. B lymphocytes were identified by expression of B220 and lack of expression of Thy 1.2. The activation status of B cells was confirmed by the increase of their FSC and expression of B7-2 and B7-1.

Figure 19 is a representation showing TLHL induced B cell activation: analysis by proliferation assay 2x10 s splenocytes from CBA/J mice were cultured and stimulated as described. On day 2 of culture the cells were pulsed for 6hrs with 3 H thymidine. The incorporation of 3 H thymidine is shown in counts per minute (cpm). MED= medium alone; TEV= TEV protease; TLHL= TLHL; TLHL+TEV= TEV-cleaved TLHL; LHL= LHL.seq.

Figure 20 is a representation showing purification of LHL-OMP on a silver stained 20% w/v polyacrylamide SDS PHAST-gel analysis of hulgG affinity column purified LHL-omp from total DH1OB cell lysate. LHL-omp was run next to a molecular size marker and shows the correct molecular weight of approximately 19.5kD.

Figure 21 is a representation showing LHL-OMP induced B cell activation. Splenocytes of C3H/HeJ mice were centrifuged in Nycodenz (1.091 g/cm 3 followed by 1 hour adherence on plastic at 37"C. Cells were stimulated at 3x10 5 per well with LPS, anti-IgM antibodies, LHL.seq at 1 jig/ml, LHL-omp at 2 ug/ml, anti CD40 mAb (clone FGK45.5) at 0.5 pg/ml, LHL-omp at 125 ng/ml and combinations of both concentrations of LHL-omp with anti- On day 1 after stimulation cells were stained for B7-1 and B7-2. B lymphocytes were identified by expression of B220 and lack of expression of Thy 1.2. The activation status of B cells was confirmed by increase of their FSC and by expression of B7-2 and/or B7-1.

WO 97/35887 PCT/AU97/00194 -37- LHL.seq data taken from representative experiments (for example, Figure 18).

Figure 22 is a representation showing LHL-OMP induced B cell proliferation. Splenocytes of C3H/HeJ mice were centrifuged in Nycodenz (1.091 g/cm 3 followed by 1 hour adherence on plastic at 37C. Cells were stimulated at 2xl0' per well with LHL.seq (l1g/ml), anti-IgM antibodies (20 pg/ml) and LHL-omp (2 pg/ml). After 2 and 3 days of culture the cells were pulsed with 'H thymidine. 'H thymidine-incorporation into DNA was assessed in a p-counter.

Figure 23 is a schematic representation of ompL.

Figure 24 is a schematic representation of Fv-catAb.

WO 97/35887 PCT/AU97/00194 -38- SUMMWARY OF SEQ U)D NOs.

MOLECULE

LBLt

CATAB-TEV

TLHL

LHL.seq FLAG epitope Kappa LHL-omp Strep-tag SEQ EID NO Nucleotide Amino acid 1 2 3 4 WO 97/35887 PCT/AU97/00194 -39- EXAMPLE 1 GENERATION OF LHL FROM SYNTHETIC OLIGONUCLEOTIDES LHL was generated from three overlapping synthetic oligos, a 115mer, a 116mer and a 105mer, using the proofreading DNA polymerase Pfu in two 20 cycle PCR reactions (see Figure The two PCR products (290bp and 200bp) were purified and blunt end cloned into the expression vector pASK75. The sequence was verified by automated sequencing. All subsequent PCRs were done in a similar fashion as described in the literature. The nucleotide and corresponding amino acid sequence for LHL is shown in SEQ ID NO: 1 and SEQ ID NO:2 respectively.

EXAMPLE 2 EXPRESSION OF LHL IN E. COLI AND PURIFICATION OVER A HUMAN IgG (hulgG) AFFINITY COLUMN The expression vector pASK75 directs protein expression via the ompA signal peptide into the periplasm of E coli. Protein expression was induced with 200ng/ml anhydrotetracycline for 16 hrs in midlog E. coli DH10B cultures. Cells were lysed and soluble LHL purified over a hulgG affinity column (Figure Extensive washes with 0.5% v/v Triton X- 100 were performed on the affinity column in order to eliminate endotoxins from the preparations. Expression levels were estimated at 20mg per litre of culture.

EXAMPLE 3 GENERATION OF AN LHL PROTEIN CARRYING THE N-TERMINAL FLAG EPITOPE AND THE C-TERMINAL STREP-TAG A form of LHL (referred to herein as "LHL.seq") was generated by PCR containing the FLAG epitope at its N-terminus and the so called strep-tag at its C-terminus (Fig.3). The nucleotide and corresponding amino acid sequence for LHL.seq is shown in SEQ ID NO:7 and SEQ ID WO 97/35887 PCT/AU97/00194 40 NO:8, respectively. The FLAG epitope comprises the amino acids DYKDDDDK (SEQ ID NO:9) and the strep-tag the amino acids AWRHPQFGG (SEQ ID NO:14). The FLAG epitope is recognised by several anti-FLAG monoclonal antibodies and the strep-tag by streptavidin.

The strep-tag was used for purification of LHL.seq over a streptavidin column. LHL.seq was washed with 0.5% v/v Triton X-100, Tween20 and PBS while bound to the column in order to minimise endotoxin levels. LHL.seq was eluted with either 100mM glycine pH2.0 or with lmg/ml diaminobiotin in PBS. In this method LHL.seq was not purified on the basis of binding immunoglobulin, thereby eliminating potential contamination of other unknown bacterial proteins which also bind immunoglobulins. The biological activity of LHL.seq, however, remained identical to that of LHL. The FLAG-epitope was added to the N-terminus in order to facilitate the secretion of LHL.seq into the periplasmic space. As in previous expression studies, this was unsuccessful and LHL.seq needed to be purified from total bacterial lysate (Fig.4). As a result of this, the ompA signal peptide is not removed, which in turn led to formation of LHL.seq multimers.

EXAMPLE 4 MITOGENIC ACTIVITY OF LHL ON B CELLS Mitogenic activity of LHL on B cells was tested in overnight cultures of splenocytes and mesenteric lymphocytes as well as on purified B cells. The activation status ofB cells was analysed by FACS, examining B cell size and induction of B7-2 surface expression. LHL's activation potency is similar to LPS (10 ig/ml), a bacterial mitogenic lipopolysaccharide and anti-IgM antibody (25 which crosslinks surface IgM. The results have been independently obtained in several different mouse strain e.g. B10.A(4R), CBA, C3H/HeJ and BALB/c. B cells showed a clear dose response to LHL when titrated in 5-fold dilutions jsg/ml to 1.6 ng/ml) in the activation assay. The results are shown in Figure 5. Parallel experiments analysing the T cell activation status within the same cultures demonstrated that LHL has no effect on T cells. T cells did not show any blast formation nor did they upregulate activation markers, e.g. IL-2 receptor alpha chain WO 97/35887 PCT/AU97/00194 -41- EXAMPLE BLOCKING OF LHL MITOGENICITY BY HuIgG In the same experiments, soluble hulgG (500 ig/ml) which binds to the L domains was used to specifically block the activity of LHL. These results rule out that B cell activation was due to a contamination of the bacterially produced LHL with endotoxins. The results are shown in Figure 6.

EXAMPLE 6 PROCESSING OF LHL BY B CELLS AND PRESENTATION OF THE H EPITOPE TO THE HEL-SPECIFIC HYBRIDOMA 3A9 Splenocytes or mesenteric lymphocytes were cocultured with the T cell hybridoma 3A9 in the presence of LHL. 3A9 is specific for the HEL peptide 52-61 aa presented on MHC II H-2AK.

Upon recognition of this peptide, 3A9 secretes IL-2. IL-2 production was measured in a bio assay which evaluates the proliferation of an IL-2 dependent cell line (CTLL) on the basis of 3 H-thymidine incorporation during DNA synthesis (Figure Presentation of H to 3A9 by B cells was clearly demonstrated by the proliferation of the CTLL and could be specifically blocked with hulgG.

EXAMPLE 7 GENERATION OF THE VARIABLE (V)-KAPPA LIGHT CHAIN ACCORDING TO THE HUMAN LEN PROTEIN SEQUENCE The amino acid sequence of the gene encoding the human myeloma protein LEN was used to generate a variable kappa light chain. This human kappa light chain protein (hereinafter referred to as "kappa") is soluble at relatively high concentrations and has been shown to bind protein L. Kappa was generated from synthetic oligonucleotides by PCR. To facilitate protein purification, a FLAG epitope was added to the N-terminus and a strep-tag to the C-terminus (Fig.8). The nucleotide and amino acid sequence of kappa is shown in SEQ ID NO:10 and 11, respectively.

WO 97/35887 PCT/AU97/00194 -42- EXAMPLE 8 EXPRESSION OF KAPPA IN E. COLIDHIOB Kappa was cloned into pASK75, allowing inducible expression of kappa into the periplasmic space of Ecoli. Expression was induced in logarithmically growing cultures of E.coli strain cells with 400ng/ml of anhydro-tetracycline for 4hrs (Fig.9).

EXAMPLE 9 PURIFICATION OF KAPPA PROTEIN FROM THE PERIPLASM OF Cultures were spun down and resuspended in a buffer containing 400mM sucrose on ice.

After 20min cells were pelleted. Kappa was then purified over an anti-FLAG and/or streptavidin column from the periplasmic fraction (Fig. EXAMPLE CONFIRMATION OF PROPER FOLDING OF KAPPA AFTER PURIFICATION The proper folding of kappa was demonstrated by its capacity to bind LHL. Kappa was bound to the streptavidin column via its strep-tag. This kappa-loaded column was then shown to bind LHL (Fig.11). The non strep-tag carrying LHL did not bind to the streptavidin column alone.

EXAMPLE 11 GENERATION OF TLHL TLHL was generated from LHL, kappa and synthetic oligonucleotides encoding a linker connecting kappa and LHL by PCR. The linker contained an amino acid sequence corresponding to the tobacco etch virus (TEV) protease recognition/cleavage site. All components were cloned into pASK75 resulting in the following protein sequence: FLAGkappa-linker-TEV-LHL-streptag (Fig.12). Potentially, TLHL could show similar characteristics as CATAB, since one kappa binding site is blocked and two are required for WO 97/35887 PCT/AU97/00194 43 surface immunoglobulin cross-linking. The nucleotide and amino acid sequences of TLHL are shown in SEQ ID NO:5 and SEQ ID NO:6, respectively.

EXAMPLE 12 EXPRESSION OF TLHL IN TLHL expression was induced in logarithmically growing cultures by addition of 400ng/ml anhydro-tetracycline for >4hrs. TLHL was not secreted into the periplasmic space and caused some cell lysis after induction.

EXAMPLE 13 PURIFICATION OF TLHL FROM TOTAL BACTERIAL LYSATE TLHL was purified via its strep-tag over a streptavidin.column from total bacterial lysate (Fig.13). Endotoxin levels were reduced using the washing protocol earlier described.

EXAMPLE 14 CLEAVAGE OF TLHL INTO AND "LHL" WITH TEV TLHL was designed so that the kappa portion of the protein could be cleaved off by the TEV protease. The TEV cleavage would generate two polypeptides, each of 172 amino acids. The identical size of the protein fragments is due to TLHL not being secreted into the periplasmic space ofEcoli and, therefore, retaining the ompA signal peptide. Incubation of TLHL with the TEV protease in PBS at room temperature or at 4"C produced therefore, a 19kD band on an SDS-PAGE gel (Fig. 14).

EXAMPLE ASSEMBLY OF CATAB-TEV FROM TLHL AND KAPPA BY PCR CATAB-TEV is assembled from TLHL and kappa by PCR. The TLHL and kappa can be linked by different peptides, for example, TNF amino acids 1-31, that are potential target sites WO 97/35887 PCT/AU97/o0194 -44for proteolytic antibodies. In this case, the linker includes a recognition sequence for the tobacco etch virus (TEV) protease which allows the generation of LHL from CATAB-TEV in vitro. The nucleotide and corresponding amino acid sequences of CATAB-TEV are shown in SEQ ID NO:3 and SEQ ID NO:4.

EXAMPLE 16 EXPRESSION OF CATAB IN DH10B AND PURIFICATION OVER A STREPTAVIDIN AFFINITY COLUMN VIA STREP-TAG CATAB-TEV is expressed and purified in the same way as TLHL (see above).

EXAMPLE 17 DEMONSTRATION OF NON-MITOGENIC ACTIVITY OF CATAB-TEV ON B CELLS CATAB-TEV is tested in the already established B cell assays which are used to analyse the mitogenic activity of LHL and LHL.seq.

EXAMPLE 18 REVELATION OF THE MITOGENIC ACTIVITY OF CATAB BY PROTEOLYTIC CLEAVAGE WITH TEV PROTEASE Digestion of CATAB-TEV with the site specific protease from TEV cleaves the covalent bond between LHL and the kappa domains. This cleavage generates the mitogenic compound LHL which is tested in the standardised B cell activation assays.

EXAMPLE 19 USAGE OF CATAB IN SEVERAL MOUSE STRAINS OF THE K-HAPLOTYPE Several mouse strains are immunised by different routes of administration, e.g. intra-splenic, in order to elicit a catalytic antibody response in vivo. The gld and lpr mutant strains are used WO 97/35887 PCT/AU97/00194 as they have been shown to have a relatively high incidence of naturally occurring catalytic auto-antibodies, e.g. antibodies with DNAse activity.

EXAMPLE DETECTION OF CATAB SPECIFIC CATALYTIC ANTIBODIES FROM THE SERUM Serum antibodies from immunised mice are purified for example on a LHL affinity column.

Purified antibodies may be incubated with 5 I-labelled CATAB and the proteolytic cleavage is evaluated on PAGE gels. In addition, streptavidin may be used to immobilise CATAB via its C-terminal strep-tag on 96 well ELISA plates. Immobilised CATAB is proteolytically cleaved by incubation with purified catalytic serum antibodies and an N-terminal affinity tag, e.g. flag epitope, is lost. This loss is detected in a sandwich ELISA assay using horse radish peroxidase (HRPO) conjugated antibodies. B cells producing catalytic antibodies can be recovered by standard hybridoma techniques and the catalytic antibodies can be humanised by recombinant DNA technology. For example, "human" antibodies can be derived from humanized mice.

EXAMPLE 21 LHL.seq INDUCED B7-1 EXPRESSION LHL.seq was tested for its ability to activate B cells as compared to stimulation with anti-IgM and anti-kappa. Activation status was measured by the induction of cell surface expression of the activation markers B7-1 and B7-2 and by entry of B cells into cell cycle. Levels of expression ofB7-1 and B7-2 were determined by flow cytometry (FACS) with fluorescencelabelled monoclonal antibodies while entry into cell cycle was monitored by an increase in cell size by Forward Light Scatter (FSC).

The method employed was as follows. Mesenteric lymphnode cells from C3H/HeJ mice were centrifuged in Nycodenz (1.091 g/cm 3 to remove dead cells and red blood cells (rbc). This WO 97/35887 PCT/AU97/00194 46was followed by 1 hour adherence on plastic at 37"C to remove adherent cells such as macrophages. Lymph node cells were stimulated in triplicate cultures 3x10 5 /well in flat bottom 96-well plates in complete RPMI 10% FCS medium at 37"C for 1-3 days. Upregulation of activation markers on B cells was monitored by gating on B220'Thyl- cells to identify B cells.

Stimulation with LPS (20 g/ml), polyclonal F(ab) 2 anti-IgM antibodies (20 pg/ml) and antikappa antibodies (10 pg/ml) were included as controls. LHL.seq was used at 1 pg/ml.

C3H/HeJ mice were used as source of lymphocytes since this particular mouse strain is nonresponsive to LPS. The use of this strain in combination with the LPS control effectively precludes the possibility that B cell stimulation induced by LHL.seq were due to LPS (endotoxin) contamination of the bacterially expressed proteins.

FACS analysis showed that this two day stimulation of C3H/HeJ lymph node cells with LPS did not result in B cell activation whereas stimulation with either anti-IgM antibodies, antikappa antibodies or LHL.seq did as measured by an increased FSC and upregulation of B7-2.

The characteristic potency of LHL.seq is demonstrated by the strong induction of B7-1 expression after incubation (see Fig. 15). Anti-IgM induces B7-1 on day 2-3. of stimulation.

EXAMPLE 22 LHL.seq INDUCED MHC CLASS HI LHL.seq was compared in its potential to ensure proper upregulation of MHC class II on stimulated B cells. Anti-IgM antibodies (20 pg/ml) as well as LHL. seq (1 pg/ml) blocked with hulgG (500 pg/ml) were included as controls. The method used was as described in Example 21.

Upregulation of MHC Class II molecules on B cells is a prerequisite to receive T cell help in vivo.

Overnight stimulation of C3H/HeJ lymph node cells with anti-IgM antibodies as well as LHL.seq did result in increased FSC and upregulation of MHC class II. LHL.seq's activities WO 97/35887 PCT/AU97/00194 -47 were completely blocked by addition of 500 pg/ml hulgG to the cultures (see Fig. 16).

EXAMPLE 23 LHL.seq INDUCED PROLIFERATION IN A DOSE DEPENDENT FASHION Serial dilutions of LHL.seq were used to stimulate B cell proliferation. The experiment demonstrated that LHL.seq's biological properties are similar to conventional B cell mitogens like anti-IgM antibodies. Thus, dose-response curves for stimulation of either mesenteric lymphnode cells from C3H/HeJ and splenocytes from CBA/J were obtained (see Fig. 17).

EXAMPLE 24 TLHL INDUCED B CELL ACTIVATION LHL.seq, TLHL and TEV-cleaved TLHL were tested for.their ability to activate B cells as measured by the induction of cell:surface expression of the activation:markers B7-1 (CD86) and B7-2 (CD80).and by entry of B cells into cell cycle. Levels of expression of B7-1 and B7- 2 were determined by flow cytometry (FACS) with fluorescence-labelled monoclonal antibodies while proliferation was monitored by an increase in cell size by Forward Light Scatter (FSC) and by 3 H-thymidine-uptake assays.

The method employed as described in Example 21.

Overnight stimulation of C3H/HeJ lymph node cells with LPS did not result in B cell activation whereas stimulation with either anti-IgM antibodies or LHL.seq did as measured by an increased FSC and upregulation of B7-2. The characteristic potency of LHL.seq is demonstrated by the strong induction of B7-1 expression after overnight incubation (see Fig.

18). Anti-IgM induces B7-1 on day 2-3 of stimulation.

TLHL, however, activated B cells to the same extent as LHL.seq. This was unexpected since it was presumed that blocking one L domain with a covalently linked kappa would prevent WO 97/35887 PCT/AU97/00194 -48crosslinking ofimmunoglobulin on the B cell surface. Prevention of crosslinking should result in no or significantly lower B cell activation than that achieved with equal amounts of LHL.seq. TEV-cleaved TLHL,.which results in omp-kappa (see below) plus the LHL.seq part, gave much lower B cell activation than uncleaved TLHL as indicated by less B7-1 and B7-2 upregulation and lower FSC increase (Fig. 18).

Splenocytes fromCBA/J mice were centrifuged in Nycodenz (1.091 g/cm 3 to remove dead cells and rbc. This was followed by 1 hour adherence on plastic at 37C to remove adherent cells. Splenocytes were then stimulated in triplicate cultures at 2xl0 5 /well in flat bottom 96well plates in complete RPMI 10% v/v FCS medium at 37"C for 2 days. Cells were pulsed for the last 6 hours with 3 H-thymidine. DNA was then harvested onto glassfibre filters and incorporation of 3 H-thymidine was measured in a P-counter.

The results obtained by FACS analysis were confirmed by the proliferation data; TLHL and LHL.seq induced equivalent B cell proliferation while TEV-cleaved TLHL was about less potent (Fig. 19).

EXAMPLE TEV-CLEAVED TLHL STIMULATION DATA CONFIRM OMP INDUCED MULTIMERISATION The B cell activation data lead the inventors to the conclusion that both LHL, LHL.seq and TLHL exist in solution as multimeric molecules. While dimeric or oligomeric immunoglobulin-binding molecules such as anti-IgM antibodies induce B cell activation, multimers such as anti-IgD-dextran result in a significantly higher degree ofB cell activation.

This is also the case with LHL, LHL.seq and TLHL in the above experiments as demonstrated by the extensive upregulation of B7-1 after overnight culture. The multimerisation is facilitated by the ompA signal peptide (omp). It has been published by others that the ompA signal peptide forms multimers in aqueous solution. Evidence for LHL, LHL.seq and TLHL aggregation has also been obtained in HPLC studies.

WO 97/35887 PCT/AU97/00194 -49- A new recombinant LHL.seq protein lacking the ompA signal peptide, called LHL-omp, was engineered which also confirms these conclusions (see below).

EXAMPLE 26 TLHL MULTIMERISATION OVERCOMES "KAPPA-BLOCKING" Although one domain should be blocked by kappa in TLHL, the multimerisation mediated by the omp allows several free domains to exist in one multimeric molecule [TLHL]. This will lead to extentive sIg crosslinking and full B cell activation as demonstrated.

EXAMPLE 27 GENERATION AND ANALYSIS OF LHL-OMP LHL-omp was generated from LHL.seq via PCR with the proofreading polymerase Pfu eliminating the ompA signal sequence.

EXAMPLE 28 AFFINITY COLUMN PURIFICATION OF LHL-OMP Although LHL-omp contains a Strep-tag, it could not be purified via the Streptavidin column using the standard protocol, indicating a lower avidity to the column matrix than that of LHL.seq. This lower avidity confirms the multimerisation of LHL.seq via omp, being the only difference between LHL.seq and LHL-omp. In agreement with this LHL-omp was readily purified over a hulgG affinity column (Fig. EXAMPLE 29 LHL-OMP INDUCED B CELL ACTIVATION The ability of LHL-omp to induce B cell activation was assessed by incubating splenocytes from C3H/HeJ mice for varying periods of time before analysing B7-1 and B7-2 expression WO 97/35887 PCT/AU97/00194 levels on B cells as outlined above. The progression of B cells into cell cycle was monitored by FACS and proliferation assays.

Cells were prepared and cultured as described above. LPS (20 tg/ml) and anti-IgM (20 lg/ml) were used as controls.

Stimulation of C3H/HeJ splenocytes with LPS did not result in detectable B cell activation whereas treatment with either anti-IgM antibodies or LHL.seq induced B cell activation during overnight culture; increased FSC and B7-2 upregulation for anti-IgM antibodies and increased FSC and B7-1 and B7-2 expression for LHL.seq. LHL-omp, used at 2 gg/ml, was less potent than LHL.seq in inducing upregulation of B7-1, B7-2 and blasting of B cells, as indicated by the FSC profile. The unchanged FSC profile indicated that LHL-omp did not induce B cell proliferation (see Fig. 21). This was confirmed in proliferation assays (Fig.22).

B cells were stimulated simultaneously with LHL-omp and anti-CD40 antibodies (mAb FGK45.5 at a concentration of 0.5 jig/ml). Anti-CD40 antibodies served as a partial substitute for T cell help. The combination of sig and helper T cell like signaling achieved good levels of B cell activation and proliferation. This could especially be demonstrated when using LHLomp at a concentration of 125 ng/ml. 125 ng/ml induced no B cell activation on its own, however, when used in combination with the anti-CD40 antibody, which by itself is also of low potency, B7-1, B7-2 and FSC upregulation were achieved. Suggesting that LHL-omp and antibodies can act synergistically (see Fig. 21).

EXAMPLE UTILISING OMP TO DESIGN A NOVEL MULTIMERIC MITOGEN Experimental data obtained show that the signal peptide from the outer membrane protein A (ompA) of E. coli induces aggregation of the recombinant proteins LHL.seq and TLHL. The ompA signal peptide (omp) is usually cleaved off once the protein reaches its destination, the bacterial periplasmic space. In the case of LHL, LHL.seq and TLHL, however, the secretion WO 97/35887 PCT/AU97/00194 -51 into the periplasm is impaired. All three proteins remain in the cytoplasm and the omp peptide forms their N-terminal part. The N-terminal omp peptide induces multimerisation as demonstrated by the potentiation of their biological activity as compared to the recombinant protein LHL-omp and TEV-cleaved TLHL.

The observation that omp induces multimerisation allows the design of simpler molecules with the same desired biological function as LHL, TLHL and CATAB. For this purpose we propose the following protein design. Above results demonstrate that the proteins described are not secreted into the periplasmic space. It should therefore be possible to produce proteins that have an omp peptide as their N-terminal part and L or HL as their C-terminal part. As omp allows the formation of multimers, this should result in the formation of [ompL],, hereafter called ompL, or [ompHL] where n is equal or larger than 2 (see Fig. 23).

EXAMPLE 31 MULTIMERISATION OF OMPL AND DESIGN OF FV-CATAB Multimerisation of ompL generates a protein complex that should allow crosslinking of surface immunoglobulins in a similar fashion to LHL or LHL.seq. OmpL itself, however, is a relatively simple monomeric protein which needs only a single blocking entity. This blocking domain will be the below described scdsFv resulting the fusion protein ompL-linker- TEV-scdsFv (Fv-catAb). The reverse of this configuration, scdsFv-TEV-linker-Lomp (pFvcatAb) will also be generated, as this might allow for periplasmic secretion of pFv-catAb.The latter pFv-catAb requires the functional multimerisation and biological activity of Lomp, a protein with the reverse fusion order of ompL and the omp peptide at its C-terminal (see Fig.

24). All described recombinant proteins are tested in the experimental systems outlined above.

EXAMPLE 32 REDESIGN OF THE L DOMAIN BLOCKING ENTITY Two potential problems are associated with the use of the LEN kappa light chain as a blocking WO 97/35887 PCT/AU97/00194 -52domain for L. First, proteins (ie. LHL, LHL.seq and TLHL) are not secreted into the periplasmic space during expression in E. coli, which might cause folding problems in the kappa portion. Secondly, there are no direct means of purifying proteins with potentially correctly folded kappas in the described system, as antibodies against kappa would be bound by LHL.seq.

In order to allow for purification of correctly folded growth factor precursors, the blocking entity was therefore redesigned. Kappa will be replaced by a single chain (sc) antibody which is stabilised by an internal disulfide bridge (disulfide bridge stabilised, ds). This scdsFv will be derived from the extensively described plasmacytoma McPc603 with antiphosphorylcholine specificity. The phosphorylcholine-binding ability will facilitate the purification of correctly folded recombinant proteins via a phosphorylcholine affinity column (see Fig. 24).

EXAMPLE 33 POTENTIAL USE OF LHL/CATAB DERIVATIVES IN HUMANS In order to enable production of catalytic antibodies in humans, slight modifications of the constructs need to be performed. The T cell epitope has to be exchanged for an "universal T cell epitope" which will be recognised by T cells in the majority of humans in conjunction with their more diverse MHC class II molecules.

Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the invention includes all such variations and modifications. The invention also includes all of the steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations of any two or more of said steps or features.

WO 97/35887 PCT/AU97/00194 -53 SEQUENCE LISTING GENERAL INFORMATION: APPLICANT: (US ONLY) AMRAD OPERATIONS PTY LTD (OTHER THAN US) Frank Koentgen, Gabriele Maria Suess, David Mathew Tarlinton and Herbert Rudolf Treutlein (ii) TITLE OF INVENTION: CATALYTIC ANTIBODIES AND A METHOD OF PRODUCING SAME (iii) NUMBER OF SEQUENCES: 12 (iv) CORRESPONDENCE ADDRESS: ADDRESSEE: DAVIES COLLISON CAVE STREET: 1 LITTLE COLLINS STREET CITY: MELBOURNE STATE: VICTORIA COUNTRY: AUSTRALIA ZIP: 3000 COMPUTER READABLE FORM: MEDIUM TYPE: Floppy disk COMPUTER: IBM PC compatible OPERATING SYSTEM: PC-DOS/MS-DOS SOFTWARE: PatentIn Release Version #1.25 (vi) CURRENT APPLICATION DATA: APPLICATION NUMBER: INTERNATIONAL APPLICATION FILING DATE: 26-MAR-1997

CLASSIFICATION:

(vii) PRIOR APPLICATION DATA: WO 97/35887 PCT/AU97/00194 54- APPLICATION NUMBER: PN8951 FILING DATE: 26-MAR-1996

CLASSIFICATION:

(vii) PRIOR APPLICATION DATA: APPLICATION NUMBER: PO5375 FILING DATE: 27-FEB-1997

CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION: NAME: HUGHES, DR E JOHN L REFERENCE/DOCKET NUMBER: EJH/AF (ix) TELECOMMUNICATION

INFORMATION:

TELEPHONE: +61 3 9254 2777 TELEFAX: +61 3 9254 2770 TELEX: AA 31787 WO 97/35887 PCT/AU97/00194 INFORMATION FOR SEQ ID NO:1: SEQUENCE CHARACTERISTICS: LENGTH: 549 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (ix) FEATURE:

NAME/KEY:

LOCATION:

CDS

1..549 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1: AAA AAG ACA GCT Lys Lys Thr Ala ATC GCG ATT GCA Ile Ala Ile Ala GCA CTG GCT GGT TTC GCT Ala Leu Ala Gly Phe Ala ACC GTA GCG CAG Thr Val Ala Gln GCC GCT CCG AAA Ala Ala Pro Lys

GAT

Asp 25 AAC ACG GAA GAA GTC Asn Thr Glu Glu Val ACG ATC Thr Ile AAA GCG AAC Lys Ala Asn CTG ATC TTT GCA Leu Ile Phe Ala GGT AGC ACA CAA ACT Gly Ser Thr Gln Thr GCA GAA TTC Ala Glu Phe AAA GGT Lys Gly ACC TTC GAA AAA Thr Phe Glu Lys

GCG

Ala 55 ACC TCG GAA GCT Thr Ser Glu Ala TAT GCG TAT GCA GAT Tyr Ala Tyr Ala Asp GAT GTT GCA GAT AAA Asp Val Ala Asp Lys

ACT

Thr TTG AAG AAA Leu Lys Lys GAC AAT Asp Asn 70 GGT GAA TAT ACT Gly Glu Tyr Thr

GTA

Val 75 192 240 288 GGT TAC ACC Gly Tyr Thr CTG AAC ATC AAA TTC GCG Leu Asn Ile Lye Phe Ala AAA GAA GCG ACC Lys Glu Ala Thr AAC CGT Asn Arg WO 97/35887 WO 9735887PCT/AU97/00194 56 AAC ACC GAC GGT TCC Asn Thr Asp Gly Ser 100 ACC GAC TAC GGT ATC TTA CAG ATC Thr Asp Tyr Gly Ile Leu Gin Ile 105 AAC TCT CGT Asn Ser Arg 110 336 TGG GGT GGT Trp Gly Gly 115 CTG ACC CTG AAA Leu Thr Leu Lys

GAA

Glu 120 GAA GTC ACG ATC AAA GCG AAC CTG Glu Val Thr Ile Lys Ala Asn Leu 125 ATC TTT Ile Phe 130 GCA AAT GGT AGC ACA CAA ACT GCA GAA Ala Asn Gly Ser Thr Gin Thr Ala Glu 135 TTC AAA GGT ACC TTC Phe Lys Gly Thr Phe 140 AAA GCG ACC TCG GAA GCT TAT GCG TAT GCA GAT ACT TTG AAG Lye Ala Thr Ser Glu Ala Tyr Ala Tyr Ala Asp Thr Leu Lys 150 155 GAC AAT GGT GAA TAT Asp Aen Gly Glu Tyr 165 ACT GTA GAT GTT GCA Thr Val Asp Val Ala 170 GAT AAA GGT TAC ACC CTG Asp Lys Gly Tyr Thr Leu 175 AAC ATC AAA TTC Aen Ile Lys Phe 180 GCG GGT TA Ala Gly INFORMATION FOR SEQ ID NO:2: SEQUENCE CHARACTERISTICS: LENGTH: 182 amino acids TYPE: amino acid TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: Met Lys Lys Thr Ala Ile Ala Ile Ala Val Ala Leu Ala Gly Phe Ala 1 5 10 Thr Val Ala Gln Ala Ala Pro Lye Asp Aen Thr Glu Glu Val Thr Ile 25 WO 97/35887 PTA9/o9 PCT/AU97/00194 57 Lye Ala Asn Leu Ile Phe Ala Asn Gly Ser Thr Gin Ala Giu Phe Lys Gly so Thr Phe Glu Lys Ala 55 Thr Ser Glu Ala Tyr Ala Tyr Ala Asp, Thr Leu Lys Lys Asp Gly Giu Tyr Thr Val Asp Vai Ala Asp Gly Tyr Thr Leu Ile Lys Phe Ala LyB Giu Ala Thr Asn Arg Aen Thr Asp Trp Gly Gly 115 Ser Thr Asp Tyr Giy 105 Ile Leu Clii Ile Asn Ser Arg 110 Ala Aen Leu Leu Thr Leu Lye Giu Val Thr Ile Lys 125 Ile Phe 130 Ala Asn Gly Ser Gin Thr Ala Glu Lye Gly Thr Phe Lye Ala Thr Ser Ala Tyr Ala Tyr Asp Thr Leu Lys Asp Asn Gly Giu Thr Val Asp Val Al a Asp 170 Lys Gly Tyr Thr Leu 175 Aen Ile Lys Phe Ala Gly 180 INFORMATION FOR SEQ ID NO:3: Wi SEQUENCE CHARACTERISTICS: LENGTH: 1491 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: DNA WO 97/35887 WO 9735887PCT/AU97/00194 58 (ix) FEATURE: NAME/KEY: CDS LOCATION: 1.-1491 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: AAA AAG ACA GCT ATC GCG ATT GCA Lys Lys Thr Ala Ile Ala Ile Ala GCA CTG GCT GGT Ala Leu Ala Gly TTC GCT Phe Ala ACC GTA GCG CAG Thr Val Ala Gin 0CC GAC TAC AAG Ala Asp Tyr Lys GAT GAC GAC AAG GAT ATC GTG Asp Asp Asp Lys Asp Ile Val ATG ACC CAG Met Thr Gin TCT CCA GAC TCC Ser Pro Asp Ser GCT GTG TCT CTG Ala Val Ser Leu

GGC

Gly GAG CGT GCC Giu Arg Ala ACC ATC Thr Ile so AAT TOC AAG TCC Asn Cys Lys Ser CAG AGT GTT TTA Gin Ser Val Leu AGC TCC AAC AGC Ser Ser Asn Ser

AAG

Lys AAC TAC CTG GCT TGO Asn Tyr Leu Ala Trp TAC CAG CAG AAA CCA GOT CAG CCT CCT AAG Tyr Gin Gin Lys Pro Oly Gin Pro Pro Lys CTG CTC ATT TAC TG Leu Leu Ile Tyr Trp, TTC AOT GGT AGC GOT Phe Ser Oly Ser Gly 100 GCA TCT ACC CGT Ala Ser Thr Arg GAA TCC GOC OTT CCT GAC CGT Giu Ser Oly Val Pro Asp Arg 90 TTC ACT CTC ACC ATC AGC AOC Phe Thr Leu Thr Ile Ser Ser 110 TCT GGT ACA Ser Oly Thr CTC CAG OCT GAA OAT OTO GCA GTT Leu Gin Ala Olu Asp Val Ala Val 11S 120 TAT TAC TGC CAG CAG TAT TAC ACT Tyr Tyr Cys Gin Gin Tyr Tyr Ser 125 ACC CCG TAC TCC TTC GOT CAG GOT ACC AAA CTO GAA ATC AAA CGC TCC Thr Pro Tyr Ser Phe Gly Gin Gly Thr Lys Leu Glu Ile Lys Arg Ser WO 97/35887 WO 9735887PCT/AU97/00194 59 130 GGT AGC GGT Gly Ser Gly 145 GGC GGT Gly Gly TCT GGT GGT GGT Ser Gly Gly Gly

GGG

Gly 155 AGC TCT GGT GGT Ser Ser Gly Gly TCT GGT GGT GGT AGC GAA AAC CTG TAC Ser Gly Gly Gly Ser Giu Asn Leu Tyr 165 CAG GGT GGT AGC Gin Gly Gly Ser GCC GAA Ala Glu 175 GA)A GTC ACG ATC AAA GCG AAC CTG ATC TTT GCA AAT GGT Glu Val Thr Ile Lye Ala Aen Leu Ile Phe Ala Aen Gly AGC ACA CAA Ser Thr Gin 190 GAA GCT TAT Giu Ala Tyr ACT GCA GAA Thr Ala Giu 195 TTC AAA GGT ACC TTC Phe Lys Gly Thr Phe 200 GAA AAA GCG ACC Glu Lys Ala Thr GCG TAT Ala Tyr 210 GCA GAT ACT TTG Ala Asp Thr Leu AAG, AAA Lys Lys 215 GAC AAT GGT Asp Asn Gly TAT ACT GTA GAT Tyr Thr Val Asp

GTT

Vai 225 GCA GAT AAA GGT Ala Asp Lys Gly TAC ACC Tyr Thr 230 CTG AAC ATC AAA Leu Aen Ile Lys 235 TTC GCG GGT AAA Phe Ala Gly Lys GCG ACC AAC CGT Ala Thr Aen Arg ACC GAC GGT TCC Thr Asp Gly Ser GAC TAC GGT ATC TTA CAG Asp Tyr Gly Ile Leu Gin 255 ATC AAC TCT Ile Aen Ser TGG GGT GGT CTG ACC Trp Gly Gly Leu Thr 265 AGC GCC GAA GAA GTC Ser Ala Glu Giu Val 270 ACG ATC Thr Ile AAA GCG AAC Lys Ala Asn 275 CTG ATC TTT GCA AAT Leu Ile Phe Ala Asn 280 GGT AGC ACA CAA ACT Gly Ser Thr Gin Thr 285 GCA GMA TTC Ala Glu Phe AAA GGT Lys Gly 290 ACC TTC GM A Thr Phe Glu Lys

GCG

Al a 295 ACC TCG GMA GCT Thr Ser Giu Ala GCG TAT GCA GAT Ala Tyr Ala Asp WO 97/35887 WO 9735887PCT/AU97/00194 TTG AAG AAA GAC Leu Lys Lys Asp

AAT

Aen 310 GGT GAA TAT ACT Gly Giu Tyr Thr GAT GTT GCA GAT Asp Val Ala Asp

AAA

Lys 320 GGT TAC ACC CTG AAC Gly Tyr Thr Leu Aen 325 ATC AAA TTC GCG Ile Lys Phe Ala GGG AGC GGC GCC Gly Ser Gly Ala 345

GGT

Gly 330 AAA GAA AGC GGT GGC GGT Lys Giu Ser Gly Gly Gly 335 960 1008 1056 1104 GGT TCT GGT Gly Ser Gly AGC GAA AAC Ser Giu Asn 355 GGT GGT Gly Gly 340 GGT GGT GGC TCT GGT GGT GGT Gly Gly Gly Ser Gly Gly Gly 350 GGC GGT GGC AGC GGC GGT GGT Gly Gly Gly Ser Giy Gly Gly 365 CTG TAC TTC CAG Leu Tyr Phe Gin GGT GGT Giy Gly 360 GGT GAT Gly Asp 370 ATC GTG ATG ACC Ile Val Met Thr CAG TCT CCA GAC TCC Gin Ser Pro Asp Ser 375 AAT TGC AAG TCC AGC Aen Cys Lys Ser Ser 395

GGC

Gly 385

AGC

Ser GAG CGT GCC ACC Giu Arg Ala Thr TCC AAC AGC AAG Ser Asn Ser Lys 405

ATC

Ile 390 CTG GCT GTG TCT CTG Leu Ala Val Ser Leu 380 CAG AGT GTT TTA TAC Gin Ser Val Leu Tyr 400 CAG CAG AAA CCA GGT Gin Gin Lye Pro Gly 415 1152 1200 1248 AAC TAC CTG GCT TGG Asn Tyr Leu Ala Trp 410 CAG CCT CCT AAG Gin Pro Pro Lye 420 CTG CTC ATT TAC Leu Leu Ile Tyr

TGG

Trp 425 GCA TCT ACC CGT Ala Ser Thr Arg GAA TCC GGC Glu Ser Gly 430 TTC ACT CTC Phe Thr Leu 1296 GTT CCT Val Pro ACC ATC Thr Ile 450

GAC

Asp 435 CGT TTC AGT GGT AGC GGT TCT GGT ACA Arg Phe Ser Gly Ser Gly Ser Gly Thr 440

GAT

Asp 445 1344 1392 AGC AGC CTC CAG GCT GAA GAT GTG GCA GTT TAT TAC TGC CAG Ser Ser Leu Gin Ala Giu Asp Val Ala Val Tyr Tyr Cys Gin 455 460 CAG TAT TAC AGT ACC CCG TAC TCC TTC GGT CAG GGT ACC AAA CTG GAA 1440 WO 97/35887 PCT/AU97/00194 61- Gin Tyr Tyr Ser 465 ATC AAA CGC AGC Ile Lys Arg Ser Thr Pro Tyr 470 GGT AGC GCT Gly Ser Ala 485 Ser Phe Gly TGG CGT CAC Trp Arg His 490 Gin Gly Thr Lys Leu Glu 475 480 CCG CAG TTC GGT Pro Gin Phe Gly GGT TAA Gly 495 1488 1491 INFORMATION FOR SEQ ID NO:4: SEQUENCE CHARACTERISTICS: LENGTH: 496 amino acids TYPE: amino acid TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4: Met Lys Lys Thr 1 Ile Ala Ile Ala Ala Leu Ala Gly Phe Ala Thr Val Ala Ala Asp Tyr Lys Asp Asp Asp Lys Asp Ile Val Met Thr Gin Ser Pro Asp Ser Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Gin Ser Val Leu Tyr Pro Gly 75 Ser Ser Asn Ser Gin Pro Pro Lys Lye Asn Tyr Leu Ala Trp 70 Tyr Gin Gin Lys Leu Leu Ile Tyr Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg WO 97/35887 WO 9735887PCT/AU97/00194 62 Phe Ser Gly Ser Gly Ser Giy Thr 100 Asp 105 Phe Thr Leu Thr Ile Ser Ser 110 Tyr Tyr Ser Leu Gin Ala 115 Giu Asp Val Ala Val 120 Tyr Tyr Cys Gin Gin 125 Thr Pro 130 Tyr Ser Phe Gly Gin 135 Gly Thr Lys Leu Giu 140 Ile Lys Arg Ser Gly 145 Ser Gly Gly Giy Gly Ser Gly Giy Gly 150 Ser Ser Gly Giy Ser Gly Gly Gly Ser 165 Glu Asn Leu Tyr Phe 170 Gin Gly Gly Ser Ala Giu 175 Giu Val Thr Thr Ala Giu 195 Lys Ala Asn Leu Ile 185 Phe Ala Asn Gly Ser Thr Gin 190 Glu Ala Tyr Phe Lys Gly Thr Giu Lys Ala Thr Ser 205 Ala Tyr 210 Ala Asp Thr Leu Lys Lys Asp Asn Gly 215 Thr Leu Asn Ile Lys Giu 220 Tyr Thr Val Asp Ala Asp Lys Gly Tyr 230 Phe Ala Gly Lys Ala Thr Asn Arg Aen 245 Thr Asp Gly Ser Thr 250 Asp Tyr Giy Ile Leu Gin 255 Ile Asn Ser Trp Giy Gly Leu Thr Ser Ala Giu Giu 265 Vai Thr Ile 270 Ala Giu Phe Lys Ala Aen 275 Leu Ile Phe Ala Gly Ser Thr Gin Lys Gly 290 Thr Phe Glu Lys Al a 295 Thr Ser Glu Ala Tyr Ala Tyr Aia Asp 300 Asp Val Ala Asp Lye Leu Lys Lys Asp Asn 310 Gly Giu Tyr Thr WO 97/35887 PTA9/09 PCT/AU97/00194 63 Gly Tyr Thr Leu Asn 325 Ile Lys Phe Ala Gly 330 Lys Giu Ser Gly Gly Gly 335 Gly Ser Gly Ser Giu Asn 355 Gly 340 Gly Gly Ser Gly Ala 345 Gly Gly Gly Ser Gly Gly Gly 350 Gly Gly Gly Leu Tyr Phe Gin Gly Gly Giy Gly Ser 365 Gly Asp 370 Ile Val Met Thr Ser Pro Asp Ser Leu Aia Val Ser Leu 380 Gly 385 Ser Giu Arg Ala Thr Ser Asn Ser Lys 405 Asn Cys Lys Ser Gin Ser Val Leu Asn Tyr Leu Ala Trp 410 Tyr Gin Gin Lys Pro Gly 415 Gin Pro Pro Val Pro Asp 435 Leu Leu Ile Tyr Ala Ser Thr Arg Giu Ser Gly 430 Phe Thr Leu Arg Phe Ser Giy Gly Ser Gly Thr Thr Ile 450 Ser Ser Leu Gin Giu Asp Val Ala Tyr Tyr Cys Gin Tyr Tyr Ser Thr Tyr Ser Phe Gly Gly Thr Lys Leu Giu 480 Ile Lys Arg Ser Ser Ala Trp Arg His 490 Pro Gin Phe Gly Gly 495 INFORMATION FOR SEQ ID SEQUENCE CHARACTERISTICS: LENGTH: 1032 base pairs WO 97/35887 PCT/AU97/00194 -64- TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (ix) FEATURE: NAME/KEY: CDS LOCATION: 1..1032 (xi) SEQUENCE DESCRIPTION: SEQ ID AAA AAG ACA GCT ATC GCG ATT GCA GTG GCA CTG GCT GGT Lys Lys Thr Ala Ile Ala Ile Ala Val Ala Leu Ala Gly TTC GCT Phe Ala ACC GTA GCG Thr Val Ala GCC GAC TAC AAG GAC Ala Asp Tyr Lys Asp GAT GAC GAC AAG GAT ATC GTG Asp Asp Asp Lys Asp Ile Val ATG ACC CAG TCT CCA GAC TCC Met Thr Gin Ser Pro Asp Ser

CTG

Leu 40 GCT GTG TCT CTG Ala Val Ser Leu GGC GAG CGT GCC Gly Glu Arg Ala ACC ATC Thr Ile AAG AAC Lys Asn AAT TGC AAG TCC Asn Cys Lys Ser CAG AGT GTT TTA TAC AGC TCC AAC AGC Gin Ser Val Leu Tyr Ser Ser Asn Ser TAC CTG GCT TGG Tyr Leu Ala Trp 70 TAC CAG CAG AAA CCA Tyr Gin Gin Lys Pro 75 GGT CAG CCT CCT AAG Gly Gin Pro Pro Lys GGC GTT CCT GAC CGT Gly Val Pro Asp Arg CTG CTC ATT TAC Leu Leu Ile Tyr GCA TCT ACC CGT Ala Ser Thr Arg

GAA

Glu TTC AGT GGT Phe Ser Gly GGT TCT GGT ACA GAT Gly Ser Gly Thr Asp 105 TTC ACT CTC ACC ATC AGC AGC Phe Thr Leu Thr Ile Ser Ser 110 WO 97/35887 WO 9735887PCT/AU97/00194 65 CTC CAG GCT Lou Gin Ala 115 GAA GAT GTG GCA GTT Glu Asp Val Ala Val 120 TAT TAC TGC CAG CAG Tyr Tyr Cys Gin Gin 125 TAT TAC AGT Tyr Tyr Ser ACC CCG Thr Pro 130 GGT AGC Gly Ser 145 TAC TCC TTC GGT Tyr Ser Phe Gly GGT ACC AAA CTG GAA ATC AAA CGC TCC Gly Thr Lys Leu Glu Ile Lys Arg Ser 140 GGT GGC GGT GGT Gly Gly Gly Gly 150 TCT GGT GGT GGT Ser Gly Gly Gly GGG AGC Gly Ser 155 TCT GGT GGT GGC Ser Gly Gly Gly 160 TCT GGT GGT GGT Ser Gly Gly Gly GAA AAC CTG TAC Glu Asn Lou Tyr

TTC

Phe 170 CAG GGT GGT AGC GCC GAA Gin Gly Gly Ser Ala Glu 17S GAA GTC ACG ATC AAA GCG AAC CTG Glu Val Thr Ile Lys Ala Asn Leu 180 TTT GCA AAT GGT Phe Ala Asn Gly AGC ACA CAA Ser Thr Gin 190 ACT GCA GAA Thr Ala Glu 195 TTC AAA GGT ACC Phe Lys Gly Thr GAA AAA GCG ACC TCG GAA GCT TAT Giu Lye Ala Thr Ser Glu Ala Tyr 205

GCG

Ala

GTT

Val 225 TAT GCA GAT ACT TTG AAG Tyr Ala Asp Thr Lou Lye 210 215 GCA GAT AAA GGT TAC ACC Ala Asp Lye Gly Tyr Thr 230 AAA GAC AAT OCT Lye Asp Asn Gly GAA TAT ACT GTA GAT Glu Tyr Thr Val Asp 220 TTC GCG GGT AAA GAA Phe Ala Gly Lys Glu 240 CTG AAC ATC Lou Asn Ile GCG ACC AAC CGT Ala Thr Asn Arg ACC GAC Thr Asp GGT TCC ACC GAC TAC GGT ATC TTA CAG Gly Ser Thr Asp Tyr Gly Ile Leu Gin 250 255 ATC AAC TCT Ile Aen Ser

CGT

Arg 260 TGG GGT GGT Trp Gly Gly CTG ACC Leu Thr 265 AGC GCC GAA GAA Ser Ala Glu Giu GTC ACG ATC Val Thr Ile 270 AAA GCG AAC CTG ATC TTT GCA AAT GGT AGC ACA CAA ACT GCA GAA TTC WO 97/35887 PCT/AU97/00194 -66- Lys Ala Asn 275 AAA GGT ACC Lys Gly Thr 290 Leu Ile Phe Ala Gly Ser Thr Gin Ala Glu Phe TTC GAA AAA Phe Glu Lys

GCG

Ala 295 ACC TCG GAA GCT TAT Thr Ser Glu Ala Tyr 300 GCG TAT GCA GAT Ala Tyr Ala Asp TTG AAG AAA GAC AAT Leu Lys Lys Asp Asn 310 GGT GAA TAT ACT Gly Glu Tyr Thr GAT GTT GCA GAT Asp Val Ala Asp GGT TAC ACC CTG AAC ATC AAA TTC GCG Gly Tyr Thr Leu Asn Ile Lys Phe Ala 325 CAC CCG CAG TTC GGT GGT TAA TA His Pro Gin Phe Gly Gly 340 INFORMATION FOR SEQ ID NO:6: AAA GAA AGC GCT Lye Glu Ser Ala TGG CGT Trp Arg 335 1008 1032 SEQUENCE CHARACTERISTICS: LENGTH: 343 amino acids TYPE: amino acid TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6: Met Lys Lys Thr Ala Thr Val Ala Gin Ala Met Thr Gin Ser Pro Ile Ala Ile Ala Val Asp Tyr Lye Asp Asp 25 Asp Ser Leu Ala Val 40 Ala Leu Ala Gly Phe Ala Asp Asp Lys Asp Ile Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lye Ser Ser Gin Ser Val Leu Tyr Ser Ser Asn Ser WO 97/35887 WO 9735887PCT/AU97/00194 67 Asn Tyr Leu Ala Tyr Gin Gin Lys Pro Gly Gin Pro Pro Leu Leu Ile Tyr Ala Ser Thr Arg Ser Giy Val Pro Asp Arg Phe Ser Gly Gly Ser Giy Thr Asp 105 Phe Thr Leu Thr Ile Ser Ser 110 Tyr Tyr Ser Leu Gin Ala 115 Giu Asp Vai Ala Vai Tyr Tyr Cye Gin 120 Thr Pro 130 Tyr Ser Phe Gly Gin Gly Thr Lys Leu 135 Ile Lys Arg Ser Gly 145 Ser Ser Gly Gly Gly Gly Gly Gly Ser 165 Ser Gly Gly Giy Ser Ser Gly Gly Gly 160 Giu Asn Leu Tyr Gin Gly Gly Ser Ala Giu 175 Giu Vai Thr Thr Aia Giu 195 Ile 180 Lys Ala Aen Leu Ile 185 Phe Aia Aen Gly Ser Thr Gin 190 Giu Ala Tyr Phe Lys Gly Thr Glu Lys Ala Thr Ser 205 Ala Tyr 210 Ala Asp Thr Leu Lys 21S Lye Asp Aen Gly Giu Tyr Thr Val Asp 220 Val 225 Ala Ala Asp Lye Gly Thr Asn Arg Aen 245 Tyr 230 Thr Leu Asn Ile Phe Ala Gly Lys Thr Asp Gly Ser Asp Tyr Gly Ile Leu Gin 255 Ile Aen Ser Arg 260 Trp Gly Gly Leu Thr 265 Ser Ala Giu Glu Val Thr Ile 270 WO 97/35887 PCT/AU97/00194 -68- Lys Ala Asn 275 Leu Ile Phe Ala Asn 280 Gly Ser Thr Gin Thr 285 Tyr Ala 300 Ala Glu Phe Lye Gly 290 Thr Phe Glu Lys Ala 295 Thr Ser Glu Ala Tyr Ala Asp Leu Lys Lys Asp Asn 310 Gly Glu Tyr Thr Asp Val Ala Asp Lys 320 Gly Tyr Thr Leu Asn 325 Ile Lys Phe Ala Gly 330 Lys Glu Ser Ala Trp Arg 335 His Pro Gln Phe Gly Gly 340 INFORMATION FOR SEQ ID NO:7: SEQUENCE CHARACTERISTICS: LENGTH: 600 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (ix) FEATURE:

NAME/KEY:

LOCATION:

CDS

1..600 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7: ATG AAA AAG ACA GCT ATC Met Lys Lys Thr Ala Ile GCG ATT Ala Ile GCA GTG GCA CTG GCT GGT TTC GCT Ala Val Ala Leu Ala Gly Phe Ala ACC GTA GCG CAG GCC GAC TAC AAG GAC GAT GAC GAC AAG GGC GCC GAA Thr Val Ala Gin Ala Asp Tyr Lys Asp Asp Asp Asp Lys Gly Ala Glu 25 WO 97/35887 WO 9735887PCT/AU97/00194 69 GAA GTC ACG Giu Val Thr ATC AAA GCG AAC CTG Ile Lys Ala Asn Leu ATC TTT GCA AAT Ile Phe Ala Aen AGC ACA CAA Ser Thr Gin ACT GCA Thr Ala so GAA TTC AAA GGT Glu Phe Lys Gly

ACC

Thr 55 TTC GAA AAA GCG ACC Phe Giu Lys Ala Thr TCG GAA GCT TAT Ser Giu Ala Tyr TAT ACT GTA GAT Tyr Thr Val Asp GCG TAT GCA GAT ACT TTG Ala Tyr Ala Asp Thr Leu 70 AAG AAA GAC AAT GGT GAA Lye Lys Asp Asn Gly Glu 75 GTT GCA GAT AAA GGT TAC ACC CTG AAC Val Aia Asp Lye Gly Tyr Thr Leu Aen

ATC

Ile 90 AAA TTC GCG GGT Lye Phe Aia Gly AAA GAA Lye Giu 288 GCG ACC AAC CGT Ala Thr Aen Arg 100 AAC ACC GAC GGT Aen Thr Asp Gly TCC ACC GAC TAC GGT ATC TTA CAG Ser Thr Asp Tyr Gly Ile Leu Gin 105 110 ATC AAC TCT Ile Asn Ser 115 CGT TGG GGT GGT CTG ACC AGC GCC GAA GAA GTC ACG ATC Arg Trp Gly Gly Leu Thr Ser Ala Giu Glu Val Thr Ile 120 125 AAA GCG Lys Ala 130 AAC CTG ATC TTT GCA Asn Leu Ile Phe Ala 135 AAT GGT AGC ACA CAA ACT GCA GAA TTC Aen Gly Ser Thr Gin Thr Ala Giu Phe 140

AAA

Lye 145 GGT ACC TTC GAA Gly Thr Phe Glu

AAA

Lys 150 GCG ACC TCG GAA GCT Ala Thr Ser Glu Ala 155 TAT GCG TAT GCA Tyr Ala Tyr Ala

GAT

Asp 160 ACT TTG AAG AAA GAC Thr Leu Lys Lye Asp 165 GGT TAC ACC CTG AAC Gly Tyr Thr Leu Aen 180 AAT GGT GAA TAT ACT Aen Gly Giu Tyr Thr 170 GTA GAT GTT GCA GAT AAA Val Asp Val Ala Asp Lye 175 480 528 576 ATC AAA TTC Ile Lys Phe GOT AAA Gly Lye GAA AGC GCT TGG CGT Giu Ser Ala Trp Arg 190 CAC CCG CAG TTC GOT GGT TAA TA WO 97/35887 WO 9735887PCT/AU97/00194 His Pro Gin Phe Gly Gly 195 INFORMATION FOR SEQ ID NO:8: SEQUENCE CHARACTERISTICS: LENGTH: 199 amino acids TYPE: amino acid TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8: Lys Lys Thr Ala Ile Ala Ile Ala Val 10 Ala Leu Ala Gly Phe Ala Thr Val Ala Ala Asp Tyr Lys Asp Asp Asp Lys Giy Ala Glu Ser Thr Gin Giu Val Thr Ile Lys Ala Asn Leu Ile Phe Ala Asn 40 Gly Thr Ala Glu Phe Lys Gly Phe Giu Lys Ala Ser Giu Ala Tyr Tyr Ala Asp Thr Lys Lys Asp Asn Glu Tyr Thr Val Val Ala Asp Lys Gly Tyr Thr Leu Asn Ile 90 Lys Phe Ala Gly Lys Glu Ala Thr Aen Ile Aen Ser 115 Asn Thr Asp Gly Thr Asp Tyr Gly Ile Leu Gin 110 Val Thr Ile Arg Trp Gly Gly Leu 120 Thr Ser Ala Glu Lye Ala 130 Aen Leu Ile Phe Ala 135 Asn Gly Ser Thr Gin Thr Ala Giu Phe WO 97/35887 PCT/AU97/00194 -71 Gly Thr Phe Glu Lys 150 Ala Thr Ser Glu Ala Tyr Ala Tyr Ala Asp Thr Leu Lys Lys Asp 165 Asn Gly Glu Tyr Val Asp Val Ala Asp Lys 175 Gly Tyr Thr Asn Ile Lys Phe Gly Lys Glu Ser Ala Trp Arg 190 His Pro Gin 195 Phe Gly Gly INFORMATION FOR SEQ ID NO:9: SEQUENCE CHARACTERISTICS: LENGTH: 8 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9: Asp Tyr Lys Asp Asp Asp Asp Lye INFORMATION FOR SEQ ID SEQUENCE CHARACTERISTICS: LENGTH: 471 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: DNA WO 97/35887 PCT/AU97/00194 -72- (ix) FEATURE: NAME/KEY: CDS LOCATION: 1..471 (xi) SEQUENCE DESCRIPTION: SEQ ID ATG AAA AAG ACA GCT ATC GCG ATT GCA GTG GCA CTG GCT GGT Met Lye Lye Thr Ala Ile Ala Ile Ala Val Ala Leu Ala Gly TTC GCT Phe Ala ACC GTA GCG CAG Thr Vai Ala Gln GCC GAC TAC AAG GAC Ala Asp Tyr Lye Asp 25 GAT GAC GAC AAG GAT ATC GTG Asp Asp Asp Lys Asp Ile Val ATG ACC CAG Met Thr Gin TCT CCA GAC TCC CTG GCT GTG TCT CTG GGC GAG CGT GCC Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Giu Arg Ala ACC ATC AAT TGC AAG TCC AGC Thr Ile Asn Cys Lye Ser Ser 55 CAG AGT GTT TTA TAC AGC TCC AAC AGC Gin Ser Val Leu Tyr Ser Ser Asn Ser

AAG

Lye AAC TAC CTG GCT Asn Tyr Leu Ala TAC CAG CAG AAA CCA Tyr Gin Gin Lye Pro GGT CAG CCT CCT Gly Gln Pro Pro CTG CTC ATT TAC TGG Leu Leu Ile Tyr Trp TTC AGT GGT AGC GGT Phe Ser Gly Ser Gly 100 CTC CAG GCT GAA GAT Leu Gin Ala Giu Asp 115 GCA TCT ACC CGT Ala Ser Thr Arg GAA TCC GGC GTT CCT GAC CGT Glu Ser Gly Val Pro Asp Arg 90 TTC ACT CTC ACC ATC AGC AGC Phe Thr Leu Thr Ile Ser Ser 110 TCT GGT ACA Ser Gly Thr GTG GCA GTT Val Ala Val 120 TAT TAC TGC CAG CAG TAT TAC AGT Tyr Tyr Cye Gin Gin Tyr Tyr Ser 125 ACC CCG TAC TCC TTC GGT CAG GGT ACC AAA CTG GAA ATC AAA CGC TCC 432 WO 97/35887 PTA9109 PCT/AU97/00194 73 Thr Pro Tyr Ser Phe 130 GGT AGC GCT TGG CGT Gly Ser Ala Trp Arg 145 Gly Gin Gly Thr Lys Leu Giu Ile Lys Arg Ser 135 140 CAC CCG CAG TTC GGT GGT TAA TA His Pro Gin Phe Gly Gly 150 155 INFORMATION FOR SEQ ID NO:1i: Wi SEQUENCE CHARACTERISTICS: LENGTH: 156 amino acids TYPE: amino acid TOPOLOGY: linear (ii) MOLECULE TYPE: protein Met 1 Thr (xi) SEQUENCE Lys Lys Thr Ala 5 Val Ala Gin Ala DESCRIPTION: SEQ ID NO:il: Ile Ala Ile Ala Val Ala Leu Ala 10 Asp Tyr Lys Ser Asp Asp Asp Lys Gly Phe Ala Asp Ile Val Giu Arg Ala Ser Asn Ser Met Thr Gin Thr Ile Asn Pro Asp Ser Val Ser Leu Gly Ser Cys Lys Ser Lys Asn Ser Tyr Ser Val Leu Tyr Leu Ala Gin Gin Lys Gin Pro Pro Leu Leu Ile Tyr Phe Ser Gly Ser 100 Ala Ser Thr Arg Ser Gly Val Pro Asp Arg Ser Ser Ser Gly Thr Asp 105 Thr Leu Thr Leu Gin Ala Giu Asp Val Ala Val Tyr Tyr Cys Gin Gin Tyr Tyr Ser WO 97/35887 PCT/AU97/00194 -74- Thr Pro 130 Tyr Ser Phe Gly Gin 135 His Pro 150 Gly Thr Lye Leu Glu Ile Lys Arg Ser 140 Ser Ala Trp Arg Gin Phe Gly Gly 155 INFORMATION FOR SEQ ID NO:12: SEQUENCE CHARACTERISTICS: LENGTH: 540 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (ix) FEATURE: NAME/KEY: CDS LOCATION: 1..540 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12: ATG GAC TAC AAG GAC GAT GAC GAC AAG Met Asp Tyr Lys Asp Asp Asp Asp Lys GGC GCC GAA GAA GTC ACG ATC Gly Ala Glu Glu Val Thr Ile AGC ACA CAA ACT GCA GAA TTC Ser Thr Gin Thr Ala Glu Phe AAA GCG AAC CTG ATC TTT GCA Lys Ala Asn Leu Ile Phe Ala AAT GGT Asn Gly 25 AAA GGT ACC Lys Gly Thr TTC GAA AAA GCG ACC TCG GAA GCT TAT GCG TAT GCA GAT Phe Glu Lys Ala Thr Ser Glu Ala Tyr Ala Tyr Ala Asp ACT TTG AAG AAA GAC AAT GGT GAA TAT ACT GTA GAT GTT GCA GAT AAA Thr Leu Lys Lys Asp Asn Gly Glu Tyr Thr Val Asp Val Ala Asp Lys WO 97/35887 PTA9/09 PCT/AU97/00194 75 TAC ACC CTG AAC ATC AAA Tyr Thr Leu Asn Ile Lys TTC GCG GGT AAA Phe Ala Gly Lys GAA GCG ACC AAC CGT Giu Ala Thr Asn Arg AAC ACC GAC GGT TCC ACC GAC TAC GGT ATC TTA CAG ATC AAC TCT CGT Asn Thr Asp Gly Ser Thr Asp Tyr Gly Ile Leu Gin Ile Asn Ser Arg TGG GGT GGT CTG ACC AGC GCC GAA Trp Gly Gly Leu Thr Ser Ala Glu 100 ATC TTT GCA AAT GGT AGC ACA CAA Ile Phe Ala Asri Gly Ser Thr Gin 115 120 GAA GTC ACG ATC AAA GCG AAC CTG Giu Val Thr Ile Lys Ala Asn Leu 105 110 ACT GCA GAA TTC AAA GGT ACC TTC Thr Ala Giu Phe Lys Gly Thr Phe 125 GAA AAA Glu Lye 130 GCG ACC TCG GAA Ala Thr Ser Glu TAT GCG TAT GCA Tyr Ala Tyr Ala GAT ACT TTG AAG AAA Asp Thr Leu Lye Lye 140 AAA GGT TAC ACC CTG Lye Gly Tyr Thr Leu 160

GAC

Asp 145 AAT GGT GAA TAT Aen Gly Giu Tyr GTA GAT GTT GCA Val Asp Val Ala

GAT

Asp 155 AAC ATC AAA TTC Aen Ile Lys Phe GGT AAA GAA AGC GCT Gly Lye Glu Ser Ala 170 TGG CGT CAC CCG CAG TTC Trp Arg His Pro Gin Phe 175 GGT GGT TAA TA Gly Gly 180 INFORMATION FOR SEQ ID NO:13: Ci) SEQUENCE CHARACTERISTICS: LENGTH: 179 amino acids TYPE: amino acid TOPOLOGY: linear WO 97/35887 WO 9735887PCT/AU97/00194 76 (ii) MOLECULE (xi) SEQUENCE TYPE: protein DESCRIPTION: SEQ ID NO:l3: Met Asp Tyr Lys Asp Asp Asp Asp Lys Gly Ala Giu Giu Val.

Thr Ile Al a Asn Leu Ile Phe Ala Asn cay 25 Ser Thr Gin Thr Lys Gly Thr Thr Leu Lys Phe Glu Lys Ala Glu Aia Tyr Al a Val Ala Giu Phe Tyr Ala Asp Ala Asp Lys Lys Asp Asn Tyr Thr Val Gly Tyr Asp Giu Thr Leu Aen Phe Ala Gly Ala Thr Asn Asn Thr Asp Gly Asp Tyr Gly Gin Ile Asn Ser Arg Trp Gly Gly Ile Phe Ala 115 Giu Lvs Ala Ser Ala Glu Thr Ile Lys Gly Ser Thr Ala Glu Phe Ala Asn Leu 110 Gly Thr Phe Leu Lys Lys Thr Ser Glu Ala Tyr Ala 130 Asp Aen Asp 140 Lys Gly Glu Tyr Asp Val Ala Gly Tyr Thr Leu 160 Phe Ile Lys Phe Lys Glu Ser Arg His Pro Gln 175 Gly Gly INFORMATION FOR SEQ ID NO:14: WO 97/35887 PCT/AU97/00194 -77- SEQUENCE CHARACTERISTICS: LENGTH: 9 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14: Ala Trp Arg His Pro Gln Phe Gly Gly

Claims (20)

1. A recombinant or synthetic growth factor precursor comprising a B cell surface molecule binding portion and an antigenic portion linked to or otherwise associated with said B cell surface molecule binding portion wherein upon a catalytic antibody on the surface of a B cell cleaving all or a portion of the antigenic portion of the recombinant or synthetic growth factor precursor, a catalytic product results which is capable of inducing B cell mitogenesis.

2. A recombinant or synthetic growth factor precursor according to claim 1 further comprising a portion capable of providing T cell dependent help for a B cell.

3. A recombinant or synthetic growth factor precursor according to claim 2 wherein the B cell surface molecule binding portion comprises a B cell surface immunoglobulin binding domain and the portion providing T cell dependent help for a B cell is a T cell epitope.

4. A recombinant or synthetic growth factor precursor according to claim 2 wherein the growth factor comprises at least two B cell surface binding portions which facilitate cross-linking of B cell surface binding molecules. A recombinant or synthetic growth factor precursor according to any one of claims 1 to 4 further comprising a portion to facilitate multimerizatiori of said precursor.

6. A recombinant or synthetic growth factor precursor according to claim 5 wherein said multimer facilitating portion is a signal peptide.

7. A recombinant synthetic growth factor precursor according to claim 6 wherein the signal peptide is from ompA or a functional equivalent thereof. 12/02 '01 MON 14:57 [TX/RX NO 8080]

12- 2-01;:11 :48 ;DAVIES COLLISON CAVE Pat. &Trad 8 3828 /1 ;61 7 3368 2262 B/ 18 79 8. A recombinant or synthetic growth factor precursor according to claim 3 wherein the B cell surface immunoglobulin binding domain is protein L from Peptostreptococcus magnus or a derivative thereof or a functional equivalent thereof. 9. A recombinant or synthetic growth factor precursor according to claim 3 wherein the T cell epitope is hen egg lysozyme (HEL) or a derivative thereof or a functional equivalent thereof. A recombinant or synthetic growth factor precursor according to any one of claims 1 to 9 comprising an amino acid sequence substantially as set forth in SEQ ID) NO:2 or having at least 60% similarity thereto. 11. A recombinant or synthetic growth factor precursor according to any one of claims 1 to 9 comprising an amino acid sequence substantially as set forth in SEQ MD NO:4 or having at least 60% similarity thereto. *12. A composition of matter comprising a growth factor precursor, said composition of matter comprising components selected from: a recombinant or synthetic molecule comprising a B cell surface immunoglobulin binding portion; a recombinant or synthetic molecule in multiineric form comprising a B cell .:surface molecule binding portion;, :(iii) a recombinant or synthetic molecule of or (ii) comprising portion providing T cell dependent help for a B cell; and (iv) separate compositions mixed prior to use or used sequentially or simultaneously comprising in a first composition a molecule having a B cell surface molecule binding portion and in a second composition a molecule capable of providing T cell dependent help for a B cell; wherein said growth factor precursor or first composition in part (iv) further comprises an antigenic portion linked to or otherwise associated with said B cell surface binding portion and upon a catalytic antibody on the surface of a B cell cleaving all or a portion of the 12/02 '01 MON 12:53 [TX/RX NO 80751 12- 2-1 ;11:48 :DAVIES COLLISON CAVL Pat, &Irad ;61 JJIJ 2262 is7 1 antigenic portion of the recombinant or synthetic growth factor precursor, a catalytic product results which is capable of inducing B cell mitogenesis.

13. A composition of matter according to claim 10 or 11 wherein the molecule providing T cell dependent help for a B cell is a T cell epitope or an anti-CD40 antibody or a functional equivalent thereof.

14. A recombinant or synthetic growth factor precursor having the structure MAX[X2]b wherein: X, is a B cell surface molecule binding entity such as a B cell surface immunoglobulin binding entity; X 2 is a portion providing T cell dependent help for a B cell; M is a portion enabling or facilitating multimer formation of the recombinant or synthetic •molecule; *e A is a target antigen for which a catalytic antibody is sought; b represents the number of X 2 molecules and may be 0, 1 or >1; C wherein upon a catalytic antibody on the surface of said B cell cleaving all or a portion of o* A from said recombinant or synthetic molecule, a catalytic product results which is capable o inducing B cell mitogenesis. S. 15. A recombinant or synthetic molecule having the structure [M].AX1 [X2]d[X3].A[M]f wherein: A is a target antigen for which a catalytic antibody is sought; 12/02 '01 MON 12:53 [TX/RX NO 8075] 12- 2-01;11:48 ;DAVIES COLLISON CAVE Pat.&Trad In1 1 3 j b 2 2tj2 9 s/ It 12- 2-01:11:48 DAVIES COLLISON CAVE P~t.&Trad :01 I 1200 2202 0/ PM)purij&h ama Ulall44n.ig.aumaiddsd o12t2mWI -81- Xi and X 3 may be the same or different and each is a B cell surface molecule binding entity; X 2 is a portion providing T cell dependent help for a catalytic antibody; M is a portion enabling or facilitating multimer formation of the recombinant or synthetic molecule; c and f may be the same of different and each is 0, 1 or >1; e is 0 or 1 with the proviso then if both c and fare 0 then e cannot be 0; d is 0 or >1; wherein upon a catalytic antibody on the surface of said B cell cleaving all or a portion of A from said recombinant or synthetic molecule, a catalytic product results which is capable of inducing B cell mitogenesis.

16. A recombinant or synthetic growth factor precursor comprising the structure: Swherein: :X and X 3 may be the same or different and each is a B cell surface molecule binding Sentity; I' and I" are optionally present and may be the same or different and each is a blocking reagent for X, and X 3 X 2 is a portion providing T cell dependent help for a B cell; wherein a catalytic antibody on the surface of said B cell is capable of cleaving all or part of A from said recombinant or synthetic molecule resulting in the molecule X 1 X 2 X 3 wherein A' is optionally present and is a portion of A after cleavage with the catalytic antibody wherein said resulting molecule is capable of inducing T cell dependent B cell mitogenesis of the B cell to which X 1 and X 3 bind. 12/02 '01 MON 12:53 [TX/RX NO 8075] 12- 2-01:11:48 :DAVIES COLLISON CAVE Pat.&Irad b1 JjjbU 22b? 5/ 1 8 r:p6arlr.amdc2d143497.koa4l.aL.«mnadakcimsdo 12/02i'I 82

17. An isolated nucleic acid molecule comprising a sequence of nucleotides encoding a recombinant growth factor according to claim 1.

18. An isolated nucleic acid molecule comprising a sequence of nucleotides encoding a recombinant growth factor precursor according to claim 12.

19. An isolated nucleic acid molecule comprising a sequence of nucleotides encoding a recombinant growth factor precursor according to claim 14. An isolated nucleic acid molecule comprising a sequence of nucleotides encoding a recombinant growth factor precursor according to claim

21. An isolated nucleic acid molecule comprising a sequence of nucleotides encoding a recombinant growth factor precursor according to claim 16.

22. An isolated nucleic acid molecule comprising a sequence of nucleotides as set forth in SEQ ID NO:1 or SEQ ID NO:3 or SEQ ID NO:7 or having at least 60% similarity thereto or capable of hybridizing thereto under low stringency conditions. oo* 23. A method for producing catalytic antibodies to a specific antigen, said method comprising administering to an animal an effective amount of a growth factor comprising an antigen capable of interacting with a B cell bound catalytic antibody said antigen fused to a B cell surface molecule binding portion for a time and under conditions for said antigen to be cleaved and for the remainder of the molecule to induce B cell mitogenesis.

24. A method according to claim 23 wherein the growth factor comprises a portion capable of providing T cell dependent help for a B cell. A method according to claim 23 further comprising the sequential or simultaneous administration of a molecule capable of providing T cell dependent help for a B cell. 12/02 '01 MON 12:53 [TX/RX NO 8075] I z z U I I I 4 tj LJMV I t VLL I UN I I I I I 4 z fF I U/ I tj 13 z-ui :11 :qu UtvItO UULL,~UN LOVO rdt. 6~rdU DI r 3300 330L W 1(2/ Id P: OlP .dlIRnod ed I dll4-PT.k0aold n.ausaHaidcdC l zl. doc. 12 D3/01 83

26. A pharmaceutical composition comprising the recombinant or synthetic growth factor precursor according to any one of claims I to 16 and one or more pharmaceutical carriers and/or diluents.

27. A recombinant or synthetic growth factor precursor which comprises the structure: AX, [X 2 [X 2 X 3 A I"]n.]m wherein: I' and I" may be the same or different and each is a blocking reagent for X, and X 3 such as a kappa or lambda light chain or an sc-ds-Fv; A is the target antigen for which a catalytic antibody is sought; X, and X 3 are B cell surface molecule binding entities; X 2 and X 2 may be the same or different and each is an entity capable or providing T cell dependent help for a B cell; o maybe 0 or 1; oo n indicates the multimeric nature of the component in parentheses and may be 0, 1 or >1; m indicates the multimeric nature of the component in parenthesis and may be I or >1.

28. A recombinant or synthetic growth factor precursor which comprises the structure: e R: A X 2 X 3 ]n[x 2 XI A IP]m :Q wherein: I' and I" may be the same or different and each is a blocking reagent for XI and X 3 such as a kappa or lambda light chain or an sc-ds-Fv; A is the target antigen for which a catalytic antibody is sought; X, and X 3 are B cell surface molecule bindingientities; X 2 and X 2 may be the same or different and each is an entity capable or providing T cell dependent help for a B cell; o maybe 0 orl; 12/02 '01 MON 12:53 [TX/RX NO 8075] le- z-U-'I I: t U /V I t UU L L I UN r i0 o,0 CCD i, Ii. I I 4 4 4 9 1 1 I tj

84- n indicates the rnultimeric nature of the component in parentheses and may be 0, 1 or >1; m indicates the niultimeric nature of the component in parenthesis and may be 1 or >1. 29. Use of the products of catalysis of a growth factor precursor to induce B cell mitogenesis to generate catalytic antibodies to a specific antigen. Use of a growth factor precursor comprising an antigen to which a catalytic antibody is sought linked, fused or otherwise associated to a B cell surface molecule binding portion in the induction of B cell initogenesis following catalytic cleavage of all or part of said antigen. 31. Use of an antigen linked, fused or otherwise associate to a B cell surface molecule binding portion in the manufacture of a growth factor precursor to induce B cell mitogenesis following catalytic cleavage of all or part of said antigen. 32. A catalytic antibody generated using the growth factor precursors thereof according to any one of claims I to 16. 33. A recombinant or synthetic growth factor precursor according to any one of claims ito I I or 16 or 27 to 28 or a composition according to any one of claims 12 or 13 or a recombinant or synthetic molecule according to any one of claims 14 or 15 or an isolated nucleic acid molecule according to any one of claims 17 to 22 or a method for producing catalytic antibodies according to any one of claims 23 to 25 or a pharmaceutical composition according to claim 26 or use according to any one of claims 29 to 31 or a catalytic atbdaccorig to claim 32 sbtnilyas hereinbefore defiedwt reference to the Figures and/or Examples. 12/02 '01 MON 12:53 LTX/RX NO 8075]